<SEC-DOCUMENT>0001628908-22-000061.txt : 20220504
<SEC-HEADER>0001628908-22-000061.hdr.sgml : 20220504
<ACCEPTANCE-DATETIME>20220504161519
ACCESSION NUMBER:		0001628908-22-000061
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220504
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220504
DATE AS OF CHANGE:		20220504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolent Health, Inc.
		CENTRAL INDEX KEY:			0001628908
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT SERVICES [8741]
		IRS NUMBER:				320454912
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37415
		FILM NUMBER:		22891690

	BUSINESS ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
		BUSINESS PHONE:		571-389-6000

	MAIL ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>evh-20220504.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:2236e70f-5c57-4add-a4a0-4a7a76be6a4b,g:bb46d4d8-91a0-4276-ac55-7a3e75c6565d,d:89fe26dc1f6a40078eca5d5f024dfa29--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>evh-20220504</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV80L2ZyYWc6MzE4NDBiNjViOTA4NDIxMWE4ZThlNmRmODkzZDAzZDcvdGFibGU6MzM3ODk2Yzg2ZWViNDUxNGFjZTc4YmIzYmU1MGVkMGUvdGFibGVyYW5nZTozMzc4OTZjODZlZWI0NTE0YWNlNzhiYjNiZTUwZWQwZV8xLTEtMS0xLTM4MDQy_8dddfbb6-c2a3-4eae-9700-d8e860886e50">May 4, 2022</ix:nonNumeric><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV80L2ZyYWc6MzE4NDBiNjViOTA4NDIxMWE4ZThlNmRmODkzZDAzZDcvdGFibGU6MzM3ODk2Yzg2ZWViNDUxNGFjZTc4YmIzYmU1MGVkMGUvdGFibGVyYW5nZTozMzc4OTZjODZlZWI0NTE0YWNlNzhiYjNiZTUwZWQwZV8zLTEtMS0xLTM4MDQy_3883474c-9753-452a-842d-fb3b67114f38">0001628908</ix:nonNumeric><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV80L2ZyYWc6MzE4NDBiNjViOTA4NDIxMWE4ZThlNmRmODkzZDAzZDcvdGFibGU6MzM3ODk2Yzg2ZWViNDUxNGFjZTc4YmIzYmU1MGVkMGUvdGFibGVyYW5nZTozMzc4OTZjODZlZWI0NTE0YWNlNzhiYjNiZTUwZWQwZV82LTEtMS0xLTM4MDQy_3574a84c-35bf-48ee-b0d3-c1fa8c1b3dd4">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="evh-20220504.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-04</xbrli:startDate><xbrli:endDate>2022-05-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i89fe26dc1f6a40078eca5d5f024dfa29_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%">UNITED STATES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WASHINGTON, D.C. 20549</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8yNzc3_fff7ea20-5f39-49a6-8674-3a1f0feb165f">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to Section 13 or 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8xNTc_8dddfbb6-c2a3-4eae-9700-d8e860886e50">May 4, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported)  &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8yNzcz_f6ab2b54-e163-4fd8-aac7-5507323b7e1c">Evolent Health, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:384.75pt"><tr><td style="width:1.0pt"></td><td style="width:109.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:6.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:103.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6NTc4ZTc0MjU4NTI5NDgwMWJkNmY4ZjM1NDUyNzY5ZjEvdGFibGVyYW5nZTo1NzhlNzQyNTg1Mjk0ODAxYmQ2ZjhmMzU0NTI3NjlmMV8wLTAtMS0xLTM4MDQy_687cfdba-5ca4-45b5-b20a-b304caa3b31b">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6NTc4ZTc0MjU4NTI5NDgwMWJkNmY4ZjM1NDUyNzY5ZjEvdGFibGVyYW5nZTo1NzhlNzQyNTg1Mjk0ODAxYmQ2ZjhmMzU0NTI3NjlmMV8wLTItMS0xLTM4MDQy_f785d71f-792a-4c72-bbdd-98300eff6bfc">001-37415</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6NTc4ZTc0MjU4NTI5NDgwMWJkNmY4ZjM1NDUyNzY5ZjEvdGFibGVyYW5nZTo1NzhlNzQyNTg1Mjk0ODAxYmQ2ZjhmMzU0NTI3NjlmMV8wLTgtMS0xLTM4MDQy_de0863b2-0aaf-496c-940b-cb9d37673d95">32-0454912</ix:nonNumeric></span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Commission File Number:&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6NTc4ZTc0MjU4NTI5NDgwMWJkNmY4ZjM1NDUyNzY5ZjEvdGFibGVyYW5nZTo1NzhlNzQyNTg1Mjk0ODAxYmQ2ZjhmMzU0NTI3NjlmMV8zLTAtMS0xLTM4MDQy_9c949cc2-def5-4c0a-a6e2-8883367cc93f">800 N. Glebe Road</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6NTc4ZTc0MjU4NTI5NDgwMWJkNmY4ZjM1NDUyNzY5ZjEvdGFibGVyYW5nZTo1NzhlNzQyNTg1Mjk0ODAxYmQ2ZjhmMzU0NTI3NjlmMV8zLTItMS0xLTM4MDQy_6407685a-75e8-4ebd-ba5d-c25a631eb89b">Suite 500</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6NTc4ZTc0MjU4NTI5NDgwMWJkNmY4ZjM1NDUyNzY5ZjEvdGFibGVyYW5nZTo1NzhlNzQyNTg1Mjk0ODAxYmQ2ZjhmMzU0NTI3NjlmMV8zLTQtMS0xLTM4MDQy_a428ffcd-6949-4623-984b-ab5e93cb780c">Arlington</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6NTc4ZTc0MjU4NTI5NDgwMWJkNmY4ZjM1NDUyNzY5ZjEvdGFibGVyYW5nZTo1NzhlNzQyNTg1Mjk0ODAxYmQ2ZjhmMzU0NTI3NjlmMV8zLTYtMS0xLTM4MDQy_64700199-a9cc-4adb-85ca-f3f9dbb13135">Virginia</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6NTc4ZTc0MjU4NTI5NDgwMWJkNmY4ZjM1NDUyNzY5ZjEvdGFibGVyYW5nZTo1NzhlNzQyNTg1Mjk0ODAxYmQ2ZjhmMzU0NTI3NjlmMV8zLTgtMS0xLTM4MDQy_fc8a21c4-03c2-4f3c-9f91-a2c9edbcf05b">22203</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Address of principal executive offices)(zip code)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8yNzc0_28908a77-036a-46b7-93c1-97408fc87be1">571</ix:nonNumeric>) <ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8yNzc4_b62cf862-90b3-4709-ba94-0a84c11aa75c">389-6000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_________________________</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8yNzc1_80f3b0d9-96cd-4a59-a38d-22b537f25f5e">&#9744;</ix:nonNumeric>  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8yNzc5_ae30188b-ac32-4976-b960-17216fb34927">&#9744;</ix:nonNumeric>  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8yNzgw_306bffd5-1cff-4732-b3d0-e4143aede0d8">&#9744;</ix:nonNumeric>  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8yNzc2_2dbc592c-3514-48c3-b33a-e63815e9cad8">&#9744;</ix:nonNumeric>  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.00pt"><tr><td style="width:1.0pt"></td><td style="width:232.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:85.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:186.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6YmViMmZlNThiZjYxNGI3NTg4NjVmNDk2YTg5OWRkOTcvdGFibGVyYW5nZTpiZWIyZmU1OGJmNjE0Yjc1ODg2NWY0OTZhODk5ZGQ5N18xLTAtMS0xLTM4MDQy_e5d9b5fa-491d-4d7e-82f0-1926abafe1f0">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6YmViMmZlNThiZjYxNGI3NTg4NjVmNDk2YTg5OWRkOTcvdGFibGVyYW5nZTpiZWIyZmU1OGJmNjE0Yjc1ODg2NWY0OTZhODk5ZGQ5N18xLTEtMS0xLTM4MDQy_77dcdadc-2e6f-4032-b5cc-7667110a6f6e">EVH</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6YmViMmZlNThiZjYxNGI3NTg4NjVmNDk2YTg5OWRkOTcvdGFibGVyYW5nZTpiZWIyZmU1OGJmNjE0Yjc1ODg2NWY0OTZhODk5ZGQ5N18xLTItMS0xLTM4MDQy_ed6b157a-2b8d-4ecc-85eb-0ebe4f0ff099">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Emerging growth company <ix:nonNumeric contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8yNzgx_a9d80e56-094a-49ad-b18e-9819f6994dce">&#9744;</ix:nonNumeric> </span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 2.02.&#160;&#160;Results of Operations and Financial Condition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;4, 2022,&#160;Evolent Health, Inc. (the "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">") issued a press release announcing its financial results for the quarter ended&#160;March&#160;31, 2022, a copy of which is furnished herewith as Exhibit 99.1.&#160;&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information, including Exhibit 99.1 hereto, furnished under this Item 2.02 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act of 1934, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Exchange Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), or otherwise subject the Company or any other person to liability under that Section, to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.&#160;&#160;Financial Statements and Exhibits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)  Exhibits</span></div><div><span><br/></span></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:473.50pt"></td><td style="width:1.0pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></td></tr><tr style="height:27pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1q22exhibit991.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1q22exhibit991.htm">Press Release dated May 4, 2022, announcing Evolent Health, Inc.'s financial results for the quarter ended March 31, 2022</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cover page from this Current Report on Form 8-K, formatted as Inline XBRL.</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;     </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;             </span></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:231.00pt"><tr><td style="width:1.0pt"></td><td style="width:82.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:144.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EVOLENT HEALTH, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/ Jonathan D. Weinberg</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jonathan D. Weinberg</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General Counsel and Secretary</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date:  May&#160;4, 2022 </span></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a1q22exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia011c00eb1e94d7fa28198ec874a61b5_1"></div><div style="min-height:40.5pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.684%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" rowspan="3" style="padding:0 1pt"><div style="text-align:center"><img alt="image0a06a.jpg" src="image0a06a.jpg" style="height:66px;margin-bottom:5pt;vertical-align:text-bottom;width:280px"></div></td></tr><tr style="height:29pt"><td colspan="3" style="display:none"></td></tr><tr style="height:29pt"><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health Announces First Quarter 2022 Results</font></div><div style="text-align:center"><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Announces Two Operating Partner Additions and One Expansion</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WASHINGTON (May&#160;4, 2022) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8211; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. (NYSE&#58; EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended March&#160;31, 2022. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Highlights from the first quarter of 2022 announcement include&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarter ended March 31, 2022&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">GAAP revenue of $297.1 million, an increase of $82.0 million, or 38.1%, from the three months ended March 31, 2021. </font></div><div style="margin-bottom:3pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.46pt">Revenue excluding revenue from divested assets increased 42.1% from the three months ended March 31, 2021.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Net loss attributable to common shareholders of Evolent Health, Inc. of $5.4 million resulting in a net loss margin of (1.8)%.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Achieved Adjusted EBITDA of $24.3 million resulting in an Adjusted EBITDA margin of 8.2%. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Total Lives on Platform of 20.3&#160;million as of March&#160;31, 2022, composed of 2.1 million Evolent Health Services Lives on Platform and 18.2 million Clinical Solutions Lives on Platform. </font></div><div><font><br></font></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also today, Evolent announced the following partnership additions&#58;</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">AvMed, a not-for-profit health plan headquartered in Miami, Florida, will expand its relationship with New Century Health, adding the Performance suite for oncology. AvMed has been a highly valued client for New Century Health's Technology and Services suite within cardiology. In addition, AvMed will adopt New Century Health&#8217;s Technology and Services radiation oncology solution to support the management of populations impacted by cancer.</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">In 2022, an independent physician group headquartered in California has engaged with Evolent Care Partners to participate in the Medicare Shared Savings Program across a portion of its Medicare fee for service population through multiple member primary care physician practices.  </font></div><div style="margin-bottom:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company announced the following partnership expansion&#58;</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Beginning in 2023, Bright Healthcare plans to significantly expand the implementation to certain Individual Family Plan membership beyond the approximately 350,000 lives that migrated to Evolent Health Services in 2022. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seth Blackley, Chief Executive Officer, and Co-Founder of Evolent Health stated, &#34;The first quarter marks a strong beginning of the year on the heels of a successful 2021. The Company continues to demonstrate strong organic growth and margin expansion, while optimizing the deployment of shareholder capital. In support of organic growth, we announced two additional operating partnerships today, bringing our total for the year to 6 versus our annual target of 6-8 new partners. We also announced an exciting client expansion for 2023. As we continue to see strong execution across the business, with particularly high growth in New Century Health and Evolent Care Partners, we remain well positioned against our near and longer-term business objectives.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Blackley added, &#34;As we look ahead for 2022, I am confident in the value of our solutions, the depth of our talent and the durability of our strategy. Together, these assets enable us to execute successfully on our mission to help transform U.S. healthcare. Because we have captured only a small fraction of our value-based-care </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addressable market, I am confident we are well positioned to grow our impact significantly throughout this year and beyond.&#34;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">Financial Results of Evolent Health, Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our earnings releases, prepared remarks, conference calls, slide presentations and webcasts, we may use or discuss non-GAAP financial measures. Definitions of the non-GAAP financial measures, as well as reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are included in this earnings release. See Financial Statement Presentation and Non-GAAP Financial Measures for more information.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Segment Highlights&#58; Clinical Solutions</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:28pt">Revenue of $190.2 million, up 46.1%, from $130.2 million from the three months ended March 31, 2021.</font></div><div style="padding-left:103.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#9642;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:27.96pt">Revenue excluding revenue from divested assets of $190.2 million, up 46.1%, from the three months ended March 31, 2021.</font></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:28pt">Adjusted EBITDA of $22.2 million and $16.0 million for the three months ended March 31, 2022 and 2021, respectively.</font></div><div style="padding-left:103.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#9642;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:27.96pt">Adjusted EBITDA margin of 11.7% and 12.3% for the three months ended March 31, 2022 and 2021, respectively.</font></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:28pt">Clinical Solutions Lives on Platform in our Performance suite was 1.5 million with a Clinical Solutions Performance suite Average PMPM of $38.07 and in our New Century Health Technology and Services suite Lives on Platform was 16.7 million with a New Century Health Technology and Services suite Average PMPM of $0.38 as of March&#160;31, 2022. </font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Segment Highlights&#58; Evolent Health Services</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:32.5pt">Revenue of $106.9&#160;million, up 25.9%, from $84.8&#160;million for the three months ended March 31, 2021.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:32.46pt">Revenue excluding revenue from divested assets of $105.2 million, up 35.4% from the three months ended March 31, 2021.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:32.5pt">Adjusted EBITDA of $8.2 million and $5.9 million for the three months ended March 31, 2022 and 2021, respectively.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:32.46pt">Adjusted EBITDA margin of 7.7% and 7.0% for the three months ended March 31, 2022 and 2021, respectively.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:32.5pt">Evolent Health Services Lives on Platform was 2.1 million with a Evolent Health Services Average PMPM of $19.17 as of March&#160;31, 2022.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reported Results </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Evolent Health, Inc. reported the following results in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue of $297.1 million and $215.1 million for the three months ended March&#160;31, 2022 and 2021, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost of revenue of $219.7 million and $157.8 million for the three months ended March&#160;31, 2022 and 2021, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Selling, general and administrative expenses of $58.9 million and $58.6 million for the three months ended March&#160;31, 2022 and 2021, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss attributable to common shareholders of Evolent Health, Inc. of $(5.4) million and $(9.8) million for the three months ended March&#160;31, 2022 and 2021, respectively.</font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Net loss margin of (1.8)% and (4.6)% for the three months ended March&#160;31, 2022 and 2021, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss attributable to common shareholders of Evolent Health, Inc., per basic and diluted share, of $(0.06) and $(0.12) for the three months ended March&#160;31, 2022 and 2021, respectively.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents was $210.2 million as of March&#160;31, 2022. </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjusted Results</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted cost of revenue of $218.5 million and $157.1 million for the three months ended March&#160;31, 2022 and 2021, respectively.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted selling, general and administrative expenses of $54.3 million and $43.0 million for the three months ended March&#160;31, 2022 and 2021, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted EBITDA of $24.3 million and $14.9 million for the three months ended March&#160;31, 2022 and 2021, respectively.</font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Adjusted EBITDA margin of 8.2% and 6.9% for the three months ended March&#160;31, 2022 and 2021, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted income (loss) attributable to common shareholders of $10.4 million and $(1.2) million for the three months ended March&#160;31, 2022 and 2021, respectively.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted income (loss) per share attributable to common shareholders of $0.12 and $(0.01) for the three months ended March&#160;31, 2022 and 2021, respectively.</font></div><div><font><br></font></div><div><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Business Outlook</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Second Quarter 2022 Guidance</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">For the three months ending June 30, 2022, revenue is expected to be in the range of approximately $290.0 million to $305.0 million. Adjusted EBITDA is expected to be in the range of approximately $18.0 million to $23.0 million.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Full Year 2022 Guidance </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Revenue for the year ending December 31, 2022 is expected to be in the range of approximately $1.16 billion to $1.21 billion. Adjusted EBITDA is expected to be in the range of approximately $85.0 million to $95.0 million.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This &#34;Business Outlook&#34; section contains forward-looking statements, and actual results may differ materially. Factors that may cause actual results to differ materially from our current expectations are set forth below in &#34;Forward Looking Statements - Cautionary Language&#34; and Evolent Health, Inc.'s filings with the Securities and Exchange Commission (&#34;SEC&#34;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Additional Outlook Information</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Cash deployed for software development is expected to be in the range of $25 million - $30 million for the year ended December 31, 2022.</font></div><div><font><br></font></div><div><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Web and Conference Call Information</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As previously announced, Evolent Health, Inc. will hold a conference call to discuss its first quarter performance this evening, May&#160;4, 2022, at 5&#58;00 p.m., Eastern Time. To listen to a live broadcast via the internet and view the accompanying materials, please visit the Company's Investor Relations website at http&#58;&#47;&#47;ir.evolenthealth.com. To participate by telephone, dial 855.940.9467 or 412.317.6034 for international callers, and ask to join the &#34;Evolent Health call.&#34; Participants are advised to dial in at least fifteen minutes prior to the call to register. The call will be archived on the company's website for one week and will be available beginning later this evening. Evolent Health invites all interested parties to attend the conference call.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Evolent Health</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health (NYSE&#58; EVH) delivers proven clinical and administrative solutions that improve whole-person health while making health care simpler and more affordable. Our solutions encompass total cost of care management, specialty care management, and administrative simplification. Evolent serves a national base of leading payers and providers, is the first company to receive the National Committee for Quality Assurance's Population Health Program Accreditation, and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolenthealth.com. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contacts&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Seth Frank</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investor Relations</font></div><div><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sfrank&#64;evolenthealth.com</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Non-GAAP Financial Measures</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to disclosing financial results that are determined in accordance with GAAP, we present and discuss Revenue Excluding Divested Assets, Adjusted Cost of Revenue, Adjusted Selling, General and Administrative Expenses, Adjusted Depreciation and Amortization Expenses, Adjusted Total Operating Expenses, Adjusted Operating Income (Loss), Adjusted EBITDA, Adjusted Earnings (Loss) Available to Common Shareholders and Adjusted Earnings (Loss) per Share Available to Common Shareholders, which are all non-GAAP financial measures, as supplemental measures to help investors evaluate our fundamental operational performance.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Cost of Revenue and Adjusted Selling, General and Administrative Expenses are defined as cost of revenue and selling, general and administrative expenses, respectively, adjusted to exclude the impact of stock-based compensation expenses, severance costs, amortization of contract cost assets recorded as a result of a one-time ASC 606 transition adjustment, acquisition-related costs related to acquisitions and business combinations, securities offerings, discontinued operations, strategy and shareholder advisory services and certain one-time adjustments. Management uses Adjusted Cost of Revenue and Adjusted Selling, General and Administrative Expenses as supplemental performance measures, which are also useful to investors, because they facilitate an understanding of our long-term operational costs while removing the effect of costs that are not expected to reoccur frequently (e.g. acquisition-related costs) and non-cash (e.g. stock-based compensation expenses) in nature. Additionally, these supplemental performance measures facilitate understanding a breakdown of our Adjusted Total Operating Expenses. Adjustments for acquisition-related costs incurred generally represent professional service fees and direct expenses related to acquisitions. Because we do not acquire businesses on a predictable cycle, we do not consider the amount of acquisition-related costs to be a representative component of the day-to-day operating performance of our business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Depreciation and Amortization Expenses is defined as depreciation and amortization expenses adjusted to exclude the impact of amortization expenses related to intangible assets acquired through asset acquisitions and business combinations. Management uses Adjusted Depreciation and Amortization Expenses as a supplemental performance measure because it reflects a complete view of the operational results. The measure is also useful to investors because it facilitates understanding a breakdown of our Adjusted Total Operating Expenses.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Total Operating Expenses is defined as the sum of Adjusted Cost of Revenue, Adjusted Selling, General and Administrative Expenses and Adjusted Depreciation and Amortization Expenses, and reflects the adjustments made in those non-GAAP measures. Adjusted Total Operating Expenses is further adjusted to exclude the impact of (gain) loss on disposal of assets and items arising from acquisitions and business combinations, such as changes in fair value of contingent consideration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Operating Income (Loss) is defined as Adjusted Revenue less Adjusted Total Operating Expenses, and reflects the adjustments made in those non-GAAP measures. Management uses Adjusted Total Operating Expenses and Adjusted Operating Income (Loss) because the removal of acquisition costs, one-time or non-cash items (e.g. depreciation, amortization and stock-based compensation expenses) allows us to focus on operational performance, and believes these measures are useful to investors because they give investors insight into our core operating performance.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is defined as net loss attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, provision for income taxes, depreciation and amortization expenses, adjusted to exclude gain on transfer of membership, loss on repayment of debt, gain from equity method investees, changes in fair value of contingent consideration, other income (expense), net, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, strategy and shareholder advisory services, acquisition-related costs and gain from discontinued operations. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management uses Adjusted EBITDA as a supplemental performance measure because the removal of acquisition-related costs, one-time or non-cash items (e.g. depreciation, amortization and stock-based compensation expenses) allows us to focus on operational performance. We believe that this measure is also useful to investors because it allows further insight into the period over period operational performance in a manner that is comparable to other organizations in our industry and in the market in general.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA Margin is as defined Adjusted EBITDA divided by Revenue. Management uses Adjusted EBITDA margin as a supplemental performance measure because it allows the investor to understand operational performance compared to revenues over time. We believe that this measure is also useful to investors because it allows further insight into the period over period operational performance in a manner that is comparable to other organizations in our industry and in the market in general.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Earnings (Loss) Available to Common Shareholders is defined as net loss attributable to common shareholders of Evolent Health, Inc. adjusted to exclude gain from equity method investees, other income (expense), net, gain on transfer of membership, loss on repayment of debt, changes in fair value of contingent consideration, purchase accounting adjustments, repositioning costs, stock-based compensation expenses, severance costs, amortization of contract cost assets recorded as a result of a one-time ASC 606 transition adjustment, gain from discontinued operations, strategy and shareholder advisory services and acquisition-related costs.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted Earnings (Loss) per Share Available to Common Shareholders is defined as Adjusted Earnings (Loss) Available to Common Shareholders divided by Weighted-Average Common Shares, and reflects the adjustments made in those non-GAAP measures.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management uses Adjusted Earnings (Loss) Available to Common Shareholders and Adjusted Earnings (Loss) per Share Available to Common Shareholders because excluding non-cash items (e.g. depreciation, amortization and stock-based compensation expenses) allows us to focus on operational performance. We believe that these measures are also useful to investors for the same reason.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue Excluding Divested Assets is defined as the sum of revenue, less revenue from our divested health plan assets of Passport, Lighthouse and Miami Children&#8217;s when divested. Management uses Total Revenue Excluding Divested Assets as a supplemental performance measure because it reflects our on-going operational results. The measure is useful to investors because it reflects the current view of our operational performance in line with how we generate our long-term forecasts.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These adjusted measures do not represent and should not be considered as alternatives to GAAP measurements, and our calculations thereof may not be comparable to similarly entitled measures reported by other companies. A reconciliation of these adjusted measures to their most comparable GAAP financial measures is presented in the tables below. We believe these measures are useful across time in evaluating our fundamental core operating performance.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#242d69;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Lives on Platform and Per Member Per Month (&#8220;PMPM&#8221;) Fee</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Lives on Platform are calculated by summing our Evolent Health Services Lives on Platform and our Clinical Solutions Lives on Platform. Evolent Health Services Lives on Platform are calculated by summing members on our value-based care and comprehensive health plan administrative platform. Clinical Solutions Lives on Platform are calculated by summing the Clinical Solutions Lives on Platform in our Performance suite and New Century Health Technology and Services suite Lives on Platform. Clinical Solutions Lives on Platform in our Performance suite are calculated by summing members covered for oncology specialty care services and members covered for cardiology specialty care services for contracts not under ASO arrangements. New Century Health Technology and Services suite Lives on Platform are calculated by summing members covered for oncology specialty care services, members covered for cardiology specialty care services and members covered for advance care planning services for contracts under ASO arrangements. Members covered for more than one category are counted in each category. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health Services average per member per month (&#8220;PMPM&#8221;) fee is defined as platform and operations revenue pertaining to the Evolent Health Services segment during the period reported divided by the average of the beginning and ending Evolent Health Services segment membership during the period reported divided by the number of months in the period. Clinical Solutions Performance suite Average PMPM fee is defined as platform and operations services revenue pertaining to our Clinical Solutions Performance suite during the period reported divided by the average of the beginning and ending Clinical Solutions Performance suite membership during the period reported divided by the number of months in the period. New Century Health Technology and Services suite Average PMPM fee is defined as platform and operations revenue pertaining to the New Century Health Technology and Services suite during the period reported divided by the average of the beginning and ending </font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Century Health Technology and Services suite membership during the period reported divided by the number of months in the period.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management uses lives on platform and PMPM fees because we believe that they provide insight into the unit economics of our services. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="ia011c00eb1e94d7fa28198ec874a61b5_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="ia011c00eb1e94d7fa28198ec874a61b5_7"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Income (Loss)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in thousands, except per share data)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:404.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,057&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,071&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219,739&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,832&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,932&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,591&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,106&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,187&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,078&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,855&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,016&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,798)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,945)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,241)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,337)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,783&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,969&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,158)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,148)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,579)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,190)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,807)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to common shareholders of Evolent Health, Inc.</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average common shares outstanding</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,509&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,670&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,807)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes, related to&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss attributable to common shareholders of Evolent Health, Inc.</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,482)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,838)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Includes $1.9&#160;million gain on disposal of discontinued operations for the three months ended March 31, 2021.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div></div></div><div id="ia011c00eb1e94d7fa28198ec874a61b5_10"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, unaudited)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:369.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:76.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,158&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,280&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,628&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,662&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,388&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523,960&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,213&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,784&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,274&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,297&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339,149&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,419,458&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,036&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,084&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, net of discount</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,598&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,676&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,940&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725,825&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611,209&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693,633&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' equity</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339,149&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,419,458&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div></div></div><div id="ia011c00eb1e94d7fa28198ec874a61b5_13"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, unaudited)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:388.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash and restricted cash used in continuing operations</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash used in operating activities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,442)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,163)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by investing activities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,766&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,951&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash used in financing activities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,376)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,584)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate on cash and cash equivalents and restricted cash</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents and restricted cash</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,156)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,795)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of beginning-of-period </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,942&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,564&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of end-of-period </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,786&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,769&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash and restricted cash provided by (used in) discontinued operations</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in investing activities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,494)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the three months ended March 31, 2021.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div></div></div><div id="ia011c00eb1e94d7fa28198ec874a61b5_16"></div><hr style="page-break-after:always"><div style="min-height:22.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of Adjusted Results of Operations</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, unaudited)</font></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:753.00pt"><tr><td style="width:1.0pt"></td><td style="width:136.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evolent Health, Inc.<br>as Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evolent Health, Inc.<br>as Adjusted</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evolent</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evolent</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evolent</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Evolent</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Health, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Health, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Health, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Health, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change Over Prior Period</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change Over Prior Period</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as Adjusted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as Reported</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as Adjusted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297,057&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297,057&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215,071&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215,071&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,986&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.1&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,986&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.1&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:36pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219,739&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,195)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218,544&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157,832&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(689)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157,143&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,907&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,401&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,932&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,674)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,258&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,591&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,570)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,021&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">341&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,237&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization expenses </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,106&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,569)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,537&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,187&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,906)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,281&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,256&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,078&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,078)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(594)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">594&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,672&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,123.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299,855&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,516)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283,339&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231,016&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,571)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209,445&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,839&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,894&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,798)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,516&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,718&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,945)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,571&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,626&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,147&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,092&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses as a percentage of total revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107.4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Adjustments to cost of revenue include $0.8 million and $0.6 million in stock-based compensation expense, $0.4 million and $0.1 million related to the amortization of contract cost assets recorded as a result of the one-time ASC 606 transition adjustment for the three months ended March 31, 2022 and 2021, respectively. </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Adjustments to selling, general and administrative expenses include $4.5 million and $3.1 million in stock-based compensation expense and $0.5 million and $2.2&#160;million of acquisition-related costs resulting from acquisitions and business combinations for the three months ended March 31, 2022 and 2021, respectively. Adjustments for the three months ended March 31, 2021 include $5.3 million of repositioning costs and $5.0 million of strategy and shareholder advisory expenses.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Adjustments to depreciation and amortization expenses of approximately $4.6&#160;million and $5.9&#160;million for the three months ended March 31, 2022 and 2021, respectively, relate to amortization of intangible assets acquired via asset acquisitions and business combinations.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div></div></div><div id="ia011c00eb1e94d7fa28198ec874a61b5_19"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Segment Results</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, unaudited)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:113.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br>Eliminations</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2022</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,318&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,057&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,057&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2021</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,286&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,223&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(438)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,071&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,071&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2022</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,217&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,196&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,413&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,158)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,255&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2021</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,942&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,976&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,918&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,011)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,907&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div id="ia011c00eb1e94d7fa28198ec874a61b5_22"></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="ia011c00eb1e94d7fa28198ec874a61b5_25"></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of Adjusted EBITDA to Net Loss</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Attributable to Common Shareholders of Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except per share data)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:398.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,807)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Net loss margin</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(1.8)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(4.6)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,241)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,337)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,202)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,106)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,187)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,969&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,158)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,783&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,078)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,380)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,346)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,706)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,000)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,994)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from discontinued operations </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,255&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,907&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA margin</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Includes $1.9&#160;million gain on disposal of discontinued operations for the three months ended March 31, 2021.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-9pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of Adjusted EBITDA to Net Loss</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Attributable to Common Shareholders of Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except per share data)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:5pt;padding-right:-9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:167.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</font></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,243)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,052&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,452&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,143&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,559)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,002)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Net income margin</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(2.1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">15.3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">7.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">8.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,241)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,337)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) for income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,202)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,624)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,068)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,482)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,119)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from equity method investees</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,783&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,969&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (gain) on disposal of assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,078)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,158)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,380)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(820)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(667)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,797)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(489)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,729)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,550)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,000)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(465)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,769)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from discontinued operations</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,217&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,942&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,196&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,976&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,158)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,011)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA margin</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13</font></div></div></div><div id="ia011c00eb1e94d7fa28198ec874a61b5_28"></div><hr style="page-break-after:always"><div style="min-height:27pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of Adjusted Earnings (Loss) Available to Common</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Shareholders to Net Loss Attributable to Common Shareholders</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except per share data)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:398.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss Attributable to Common Shareholders of Evolent Health, Inc. (a)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,350)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,807)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,783&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,969&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on repayment of debt</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,158)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,078)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase accounting adjustments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,569)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,906)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,380)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,346)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,706)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from discontinued operations </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,000)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(457)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,994)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted Income (Loss) Attributable to Common Shareholders (b)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,392&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,199)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per Share Attributable to Common Shareholders - Basic and Diluted (a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.06)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted Income (Loss) per Share Available to Common Shareholders (b)</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares - basic and diluted </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,509&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,670&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes $1.9&#160;million gain on disposal of discontinued operations for the three months ended March 31, 2021.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">For periods of net loss, shares used in both the basic and diluted earnings per share calculation represent basic shares as using diluted shares would be anti-dilutive.</font></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14</font></div></div></div><div id="ia011c00eb1e94d7fa28198ec874a61b5_31"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of Revenue from Divested Assets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">to Revenue</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands, except per share data)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,057&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,071&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from divested assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,211&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue excluding divested assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,399&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,860&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Solutions revenue</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,223&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from divested assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Solutions revenue excluding divested assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,199&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,152&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evolent Health Services revenue</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,858&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,848&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from divested assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,140&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evolent Health Services revenue excluding divested assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,200&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,708&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue excluding divested assets</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,399&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,860&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15</font></div></div></div><div id="ia011c00eb1e94d7fa28198ec874a61b5_34"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Evolent Health, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Guidance Reconciliation</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands, unaudited)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:329.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:81.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:91.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended June 30, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year <br>Ended December<br>31, 2022</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to common shareholders of Evolent Health, Inc.</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,625)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,690)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,500)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,741)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,202)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,250)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,811)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in contingent consideration</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,100)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,300)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,500)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,846)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,000)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,457)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,500&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,000&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance reconciliation provided above reconciles the midpoint of the respective guidance ranges to the most comparable GAAP measure.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16</font></div></div></div><div id="ia011c00eb1e94d7fa28198ec874a61b5_37"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS - CAUTIONARY LANGUAGE</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements made in this report and in other written or oral statements made by us or on our behalf are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 (&#8220;PSLRA&#8221;). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like&#58; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;aim,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;shall,&#8221; &#8220;may,&#8221; &#8220;might&#8221; and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to our ability to grow our impact significantly throughout this year and beyond, future actions, trends in our businesses, prospective services, new partner additions&#47;expansions, our guidance and business outlook and future performance or financial results, and the closing of pending transactions and the outcome of contingencies, such as legal proceedings. We claim the protection afforded by the safe harbor for forward-looking statements provided by the PSLRA.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements are only predictions based on our current expectations and projections about future events. Forward-looking statements involve risks and uncertainties that may cause actual results, level of activity, performance or achievements to differ materially from the results contained in the forward-looking statements.&#160;Risks and uncertainties that may cause actual results to vary materially, some of which are described within the forward-looking statements, include, among others&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:32.5pt">the significant portion of revenue we derive from our largest partners, and the potential loss, non-renewal, termination or renegotiation of our relationship or contract with any significant partner, or multiple partners in the aggregate&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">evolution in the market for value-based care&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">uncertainty in the health care regulatory framework, including the potential impact of policy changes&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to offer new and innovative products and services&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to completed and future acquisitions, investments, alliances and joint ventures, divert management resources, or result in unanticipated costs or dilute our stockholders&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the financial benefits we expect to receive as a result of the sale of certain assets of Passport may not be realized&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the growth and success of our partners, which is difficult to predict and is subject to factors outside of our control, including governmental funding reductions and other policy changes, enrollment numbers for our partners&#8217; plans, premium pricing reductions, selection bias in at-risk membership and the ability to control and, if necessary, reduce health care costs&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks relating to our ability to maintain profitability for our total cost of care and New Century Health&#8217;s performance-based contracts and products, including capitation and risk-bearing contracts&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to effectively manage our growth and maintain an efficient cost structure, and to successfully implement cost cutting measures&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in general economic conditions nationally and regionally in our markets, including inflation and economic and business conditions and the impact thereof on the economy resulting from the COVID-19 pandemic and other public health emergencies&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to recover the significant upfront costs in our partner relationships&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract new partners and successfully capture new growth opportunities&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the increasing number of risk-sharing arrangements we enter into with our partners&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to estimate the size of our target markets&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to maintain and enhance our reputation and brand recognition&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">consolidation in the health care industry&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">competition which could limit our ability to maintain or expand market share within our industry&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to governmental payer audits and actions, including whistleblower claims&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to partner with providers due to exclusivity provisions in our contracts&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to our offshore operations&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to contain health care costs, implement increases in premium rates on a timely basis, maintain adequate reserves for policy benefits or maintain cost effective provider agreements&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our dependency on our key personnel, and our ability to attract, hire, integrate and retain key personnel&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of additional goodwill and intangible asset impairments on our results of operations&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our indebtedness, our ability to service our indebtedness, and our ability to obtain additional financing&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to achieve profitability in the future&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of litigation, including the ongoing class action lawsuit&#59;</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">material weaknesses in the future may impact our ability to conclude that our internal control over financial reporting is not effective and we may be unable to produce timely and accurate financial statements&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions and penalties as a result of privacy and data protection laws&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">data loss or corruption due to failures or errors in our systems and service disruptions at our data centers&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions and penalties as a result of privacy and data protection laws&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">adequate protection of our intellectual property, including trademarks&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any alleged infringement, misappropriation or violation of third-party proprietary rights&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our use of &#8220;open source&#8221; software&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to protect the confidentiality of our trade secrets, know-how and other proprietary information&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on third parties and licensed technologies&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to use, disclose, de-identify or license data and to integrate third-party technologies&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our partners&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on third-party vendors to host and maintain our technology platform&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations to make payments to certain of our pre-IPO investors for certain tax benefits we may claim in the future&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to utilize benefits under the tax receivables agreement described herein&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations to make payments under the tax receivables agreement that may be accelerated or may exceed the tax benefits we realize&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the terms of agreements between us and certain of our pre-IPO investors&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the conditional conversion features of the 2024 and 2025 convertible notes, which, if triggered, could require us to settle the 2024 or 2025 convertible notes in cash&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential volatility of our Class A common stock price&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential decline of our Class A common stock price if a substantial number of shares are sold or become available for sale&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions in our second amended and restated certificate of incorporation and third amended and restated by-laws and provisions of Delaware law that discourage or prevent strategic transactions, including a takeover of us&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability of certain of our investors to compete with us without restrictions&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions in our second amended and restated certificate of incorporation which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our intention not to pay cash dividends on our Class A common stock.</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The risks included here are not exhaustive. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements.  Our Annual Report on Form 10-K for the year ended December 31, 2021 (the &#34;2021 Form 10-K&#34;) and other documents filed with the SEC include additional factors that could affect our businesses and financial performance. Moreover, we operate in a rapidly changing and competitive environment.  New risk factors emerge from time to time, and it is not possible for management to predict all such risk factors.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is not possible to assess the effect of all risk factors on our businesses or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. In addition, we disclaim any obligation to update any forward-looking statements to reflect events or circumstances that occur after the date of this report.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>evh-20220504.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2236e70f-5c57-4add-a4a0-4a7a76be6a4b,g:bb46d4d8-91a0-4276-ac55-7a3e75c6565d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:evh="http://www.evolenthealth.com/20220504" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.evolenthealth.com/20220504">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20220504_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20220504_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20220504_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPageCoverPage" roleURI="http://www.evolenthealth.com/role/CoverPageCoverPage">
        <link:definition>0001001 - Document - Cover Page Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>evh-20220504_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2236e70f-5c57-4add-a4a0-4a7a76be6a4b,g:bb46d4d8-91a0-4276-ac55-7a3e75c6565d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CoverPageCoverPage" xlink:type="simple" xlink:href="evh-20220504.xsd#CoverPageCoverPage"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CoverPageCoverPage" xlink:type="extended" id="ie01eca984dcc4d54a6c94239d6ff9aba_CoverPageCoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c97dd1fb-9c11-444c-bfa9-87550c9c232a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_Security12bTitle_c97dd1fb-9c11-444c-bfa9-87550c9c232a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5e58632b-f014-4a8d-b196-7173f85a289f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5e58632b-f014-4a8d-b196-7173f85a289f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a54034ce-712b-473b-9340-1c6cefcc6cea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_DocumentType_a54034ce-712b-473b-9340-1c6cefcc6cea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5374d209-2ee1-47a2-afbd-5a52c37d52f7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityRegistrantName_5374d209-2ee1-47a2-afbd-5a52c37d52f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c9b0e4d4-a24c-4602-9dd3-12fce7fea1f5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_CityAreaCode_c9b0e4d4-a24c-4602-9dd3-12fce7fea1f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_73f055dc-e1cc-42a2-b5e0-ad0683fb7a90" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_LocalPhoneNumber_73f055dc-e1cc-42a2-b5e0-ad0683fb7a90" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_595132ee-2f8f-4811-94ff-ae995de2b016" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityFileNumber_595132ee-2f8f-4811-94ff-ae995de2b016" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d7e536be-dc29-4902-9696-894d5876ff17" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityTaxIdentificationNumber_d7e536be-dc29-4902-9696-894d5876ff17" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cfc07de0-43c8-4162-8ac6-6759cb2c5449" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityAddressAddressLine1_cfc07de0-43c8-4162-8ac6-6759cb2c5449" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_33a85e0e-4b25-40df-9b25-b6907f10be67" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityAddressAddressLine2_33a85e0e-4b25-40df-9b25-b6907f10be67" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_97c008c4-c038-468b-974f-6d852eb7e37a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityAddressCityOrTown_97c008c4-c038-468b-974f-6d852eb7e37a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_91f8b61f-716d-4682-8393-d4579a34a7f9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityAddressStateOrProvince_91f8b61f-716d-4682-8393-d4579a34a7f9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d5c8c3da-042d-4274-9db2-83a97d1a279e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityAddressPostalZipCode_d5c8c3da-042d-4274-9db2-83a97d1a279e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_5a5fe38b-5955-4afe-a39a-31aba107fb88" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_WrittenCommunications_5a5fe38b-5955-4afe-a39a-31aba107fb88" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_362071d3-637a-420e-9986-0e89d0b38485" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_SolicitingMaterial_362071d3-637a-420e-9986-0e89d0b38485" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_35106772-94d4-41f7-afa5-238bd67bd2bb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_PreCommencementTenderOffer_35106772-94d4-41f7-afa5-238bd67bd2bb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_995053c4-c9ea-4326-bd63-348633e38e3a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_995053c4-c9ea-4326-bd63-348633e38e3a" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_08f906e0-a7fd-48f9-8a11-594dd0dc2639" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityEmergingGrowthCompany_08f906e0-a7fd-48f9-8a11-594dd0dc2639" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c9fd9ef1-e5e3-4b50-8f75-d2f12b3d7f33" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_TradingSymbol_c9fd9ef1-e5e3-4b50-8f75-d2f12b3d7f33" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_16e4e922-b43e-42c3-959a-e614ac6f4b28" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_SecurityExchangeName_16e4e922-b43e-42c3-959a-e614ac6f4b28" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6053f306-334b-456b-83fb-b26f5047068a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_DocumentPeriodEndDate_6053f306-334b-456b-83fb-b26f5047068a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_dd06849c-9b28-4ecc-b2df-2adfe20109fc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityCentralIndexKey_dd06849c-9b28-4ecc-b2df-2adfe20109fc" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_27329da0-e74d-4dfc-93da-0abcda0e84e5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_AmendmentFlag_27329da0-e74d-4dfc-93da-0abcda0e84e5" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_7f300aa3-3a17-4cf7-9568-87c35cb986af" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_DocumentInformationTable_7f300aa3-3a17-4cf7-9568-87c35cb986af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationDocumentAxis_ec0bfa6a-16b6-4662-994e-f88cff2456d8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationDocumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_7f300aa3-3a17-4cf7-9568-87c35cb986af" xlink:to="loc_dei_DocumentInformationDocumentAxis_ec0bfa6a-16b6-4662-994e-f88cff2456d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentDomain_ec0bfa6a-16b6-4662-994e-f88cff2456d8_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_DocumentInformationDocumentAxis_ec0bfa6a-16b6-4662-994e-f88cff2456d8" xlink:to="loc_dei_DocumentDomain_ec0bfa6a-16b6-4662-994e-f88cff2456d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentDomain_c3602bc3-3666-47ad-a698-aaf6fd0990a3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_DocumentInformationDocumentAxis_ec0bfa6a-16b6-4662-994e-f88cff2456d8" xlink:to="loc_dei_DocumentDomain_c3602bc3-3666-47ad-a698-aaf6fd0990a3" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>evh-20220504_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2236e70f-5c57-4add-a4a0-4a7a76be6a4b,g:bb46d4d8-91a0-4276-ac55-7a3e75c6565d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_93bc5c2a-4363-45db-961c-05e7d8f65069_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_75eb90d6-7945-4ae9-a514-0a86043ed3af_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentDomain_b11e5f23-8fde-4471-948c-6d889adb54cd_terseLabel_en-US" xlink:label="lab_dei_DocumentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document [Domain]</link:label>
    <link:label id="lab_dei_DocumentDomain_label_en-US" xlink:label="lab_dei_DocumentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentDomain" xlink:to="lab_dei_DocumentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c7dc7191-5ed8-49ce-975a-9396f6cb746a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2dd35f38-c78a-45c9-acd1-b0d165f2157e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_8f9168fb-4dc7-4939-86fd-d7eeae0f5cf3_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_665d41f4-8b44-4aef-9729-61d5aa6f679b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c0577fe4-1e35-4af9-8b5e-918512e11815_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_492b9c18-7e3f-46a4-9395-a16afe24f090_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_12f9bc51-312b-449e-a322-4e6eaa5d5b01_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a3028fd3-8c2e-45a1-a0eb-cb052ac3853d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_3513b38a-12df-4a91-a1aa-59e116a36b1e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4fab8593-dd08-42c9-96cd-1fab7bd053d9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_82e4e2f9-464b-46bb-865c-57a14400b209_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_4bdee0e4-389e-4fab-8faf-0b0c467cccb4_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_d2499cce-a987-48c5-aaf2-e7bd51cb11c2_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ff3ddca7-84df-4872-a8d2-17b16759b8fd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_32bec900-f220-4716-a260-24ad74aaf166_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c4996ef2-9658-4a6d-9672-a4d1439041eb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_c14b0320-7bc9-401a-aae4-b2643029b059_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_fe02ccee-5adf-4132-87b0-6420bbc4290d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4708bbf6-2054-49aa-a9a9-58e618d9495c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_ea6e5516-2603-4e9e-b865-62055542b82b_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_49f6fb21-69d2-4a37-8301-6a935c268962_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationDocumentAxis_0ea5aa0e-0a10-4343-aac4-9abe950f1973_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationDocumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information, Document [Axis]</link:label>
    <link:label id="lab_dei_DocumentInformationDocumentAxis_label_en-US" xlink:label="lab_dei_DocumentInformationDocumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information, Document [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationDocumentAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationDocumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationDocumentAxis" xlink:to="lab_dei_DocumentInformationDocumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2aec4228-091c-4cb1-8f04-04b6adca8d97_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f82d1939-8afa-4d81-8b73-59635c7a5c7d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1505eb9f-40a9-4287-b9eb-09a06525989e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>evh-20220504_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:2236e70f-5c57-4add-a4a0-4a7a76be6a4b,g:bb46d4d8-91a0-4276-ac55-7a3e75c6565d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CoverPageCoverPage" xlink:type="simple" xlink:href="evh-20220504.xsd#CoverPageCoverPage"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CoverPageCoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_1e90fdb3-12fe-4ba6-92ad-1ec75f5d4dc4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_7f300aa3-3a17-4cf7-9568-87c35cb986af" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_1e90fdb3-12fe-4ba6-92ad-1ec75f5d4dc4" xlink:to="loc_dei_DocumentInformationTable_7f300aa3-3a17-4cf7-9568-87c35cb986af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationDocumentAxis_ec0bfa6a-16b6-4662-994e-f88cff2456d8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationDocumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_7f300aa3-3a17-4cf7-9568-87c35cb986af" xlink:to="loc_dei_DocumentInformationDocumentAxis_ec0bfa6a-16b6-4662-994e-f88cff2456d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentDomain_c3602bc3-3666-47ad-a698-aaf6fd0990a3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationDocumentAxis_ec0bfa6a-16b6-4662-994e-f88cff2456d8" xlink:to="loc_dei_DocumentDomain_c3602bc3-3666-47ad-a698-aaf6fd0990a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_7f300aa3-3a17-4cf7-9568-87c35cb986af" xlink:to="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c97dd1fb-9c11-444c-bfa9-87550c9c232a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_Security12bTitle_c97dd1fb-9c11-444c-bfa9-87550c9c232a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5e58632b-f014-4a8d-b196-7173f85a289f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5e58632b-f014-4a8d-b196-7173f85a289f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a54034ce-712b-473b-9340-1c6cefcc6cea" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_DocumentType_a54034ce-712b-473b-9340-1c6cefcc6cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5374d209-2ee1-47a2-afbd-5a52c37d52f7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityRegistrantName_5374d209-2ee1-47a2-afbd-5a52c37d52f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c9b0e4d4-a24c-4602-9dd3-12fce7fea1f5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_CityAreaCode_c9b0e4d4-a24c-4602-9dd3-12fce7fea1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_73f055dc-e1cc-42a2-b5e0-ad0683fb7a90" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_LocalPhoneNumber_73f055dc-e1cc-42a2-b5e0-ad0683fb7a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_595132ee-2f8f-4811-94ff-ae995de2b016" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityFileNumber_595132ee-2f8f-4811-94ff-ae995de2b016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d7e536be-dc29-4902-9696-894d5876ff17" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityTaxIdentificationNumber_d7e536be-dc29-4902-9696-894d5876ff17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cfc07de0-43c8-4162-8ac6-6759cb2c5449" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityAddressAddressLine1_cfc07de0-43c8-4162-8ac6-6759cb2c5449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_33a85e0e-4b25-40df-9b25-b6907f10be67" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityAddressAddressLine2_33a85e0e-4b25-40df-9b25-b6907f10be67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_97c008c4-c038-468b-974f-6d852eb7e37a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityAddressCityOrTown_97c008c4-c038-468b-974f-6d852eb7e37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_91f8b61f-716d-4682-8393-d4579a34a7f9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityAddressStateOrProvince_91f8b61f-716d-4682-8393-d4579a34a7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d5c8c3da-042d-4274-9db2-83a97d1a279e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityAddressPostalZipCode_d5c8c3da-042d-4274-9db2-83a97d1a279e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_5a5fe38b-5955-4afe-a39a-31aba107fb88" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_WrittenCommunications_5a5fe38b-5955-4afe-a39a-31aba107fb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_362071d3-637a-420e-9986-0e89d0b38485" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_SolicitingMaterial_362071d3-637a-420e-9986-0e89d0b38485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_35106772-94d4-41f7-afa5-238bd67bd2bb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_PreCommencementTenderOffer_35106772-94d4-41f7-afa5-238bd67bd2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_995053c4-c9ea-4326-bd63-348633e38e3a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_995053c4-c9ea-4326-bd63-348633e38e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_08f906e0-a7fd-48f9-8a11-594dd0dc2639" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityEmergingGrowthCompany_08f906e0-a7fd-48f9-8a11-594dd0dc2639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c9fd9ef1-e5e3-4b50-8f75-d2f12b3d7f33" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_TradingSymbol_c9fd9ef1-e5e3-4b50-8f75-d2f12b3d7f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_16e4e922-b43e-42c3-959a-e614ac6f4b28" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_SecurityExchangeName_16e4e922-b43e-42c3-959a-e614ac6f4b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6053f306-334b-456b-83fb-b26f5047068a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_DocumentPeriodEndDate_6053f306-334b-456b-83fb-b26f5047068a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_dd06849c-9b28-4ecc-b2df-2adfe20109fc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_EntityCentralIndexKey_dd06849c-9b28-4ecc-b2df-2adfe20109fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_27329da0-e74d-4dfc-93da-0abcda0e84e5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9b00906a-d742-412a-a4b1-534f7afd7cec" xlink:to="loc_dei_AmendmentFlag_27329da0-e74d-4dfc-93da-0abcda0e84e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image0a06a.jpg
<TEXT>
begin 644 image0a06a.jpg
M_]C_X0^"17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    D    <@$R  (    4
M    EH=I  0    !    K    -@ +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-#(#(P,3<@*$UA8VEN=&]S:"D ,C Q-SHP,SHQ,B Q-#HP-3HS
M,0     #H $  P    $  0  H ( !     $   0:H , !     $   #Z
M      8! P #     0 &   !&@ %     0   28!&P %     0   2X!*  #
M     0 "   " 0 $     0   38" @ $     0  #D0         2     $
M  !(     ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ,
M" @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,
M# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,
M#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  F
M * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%
M!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%
M!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<E
MDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D
M]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'
M!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q
M)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75
MY?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#T/J_UBZ+T
M1K'=3RV8YL^A7J^QW\IE%0LN<W^7Z:%TCZU_5[K5IHZ=FLMO:)]%P=581^\R
MK(9598UOYVQ>2U]5Z/G_ %BR.J_6A]KL.YSWBJN27:[<7%+F.8^NBBC]Q_YG
M\NQ#Z]U+ZM5YU&?]4[+,4TS8:[)'IW,(=390ZU]CMMOO;;5]#_MU61RXV]7%
M7S?H+>)]=9];OJZ_JO['&8!U#U#1Z#F6-/J-!=LWOK;5^;[/?^D_,5SJG5NG
M](Q#F]1N&/CM<UA>07>YQVL:&UA[W?YJ\R^OU5M.?TOZUX+=G[1JIR!&H&30
M&9%&X_1_2T>FS_T%5G_&5US]J,Z-@X =8W)J9GLKC5SL@>AT]G]9V_(31A!,
M*NI7Q>'#\RN+=] P.O=(ZAT]_4\7):<&LN#\AX=4P;/YPEV0VKV,_P!)]!99
M_P 8GU-%GI_M$<QO%5Q9_P!O"GT=O\O>N'^O;;NET])^J6.X?9\7&KML&H;;
MD6V/J]6W^2VZNV[_ *__ ,&Q=4/\5OU>_9OV<NN.=M_Y0WNW;_W_ +-O^R^G
MN_P/I_S?^$]3]*E[>, &1E4CZ:_=_K*L]'KL?(Q\FEF1C6LOIL$LMK<'L</%
MCV2UR\I_Q2_^**__ ,(O_P#/U"M?XK<_+Q>MY?1+732]EECF"2UM]%C*+7U?
MNMN:_P!__%5*G_BJL;5US*M=]&OI]CC'@+:7)PAP1RQWTC2+LA](ZQ]9NA=$
M+&]3RV466#<RH!S["-1O]&EMENSV_P YLV)NC_6CH/6WOKZ9F,OMK&YU)#J[
M WC?Z-[:[?3]WT]FQ>0=+ZET/+ZO=U;ZW/MN9DCU357N/J6.^@RQ[7LL9C8M
M/LII:_\ T?\ @Z_3LCU;JW0,/K%'5/JG990RB+13:2-EK#[F5.>]UC\?*J]E
MM.[_ $GYEGIL7W<;>KBKYO\ )IXGV#JOUKZ!T?+9A=1RQ1DV,;8RO98Z6O<Z
MICIJK>WW65O5?-^O7U4P<Q^%D]0:V^IVRT-98]K'#Z3++JJWTL<S_"?I/T7^
M$7 _XT;/4^LF,^L_SF!06$_RKLK:?^DK_P!<OJ)T?H?U=;GX#K1D8SZV6NL>
M7"T6/;2XNK/Z.I[7V>HWT&UH#%CJ'$3<^W=5G7P>L^M_UBHZ9]7K,G%RVU9.
M76?V;:P>H'OV^K7Z;MMM.U[/S[/T:Y_ZE?7RMU5U/UCZEOR[<AC,1KJH):X,
M8/Z)2VOW7N_/69@X>/G_ .*^^_*:7V=(?DNPB'%H8=V[Z+3ML;^E?[+%/_%U
M]6ND=8HR<O/J?9?AY3/0<VQ[ -K:[VRRMS6/_2_OH\$(PGQ6>&56-U6;#ZBL
MGJG6VXMOV3' LR=-Q/T63]&?WK'?N*[U'+&#@7Y9$^C6YX![D#V-_M.7F'4\
M[*;TW(?476Y>014TLU>ZR]PK=LC_  C][MBHYN,B,,9X99)<'%^[_+B8LV?A
MG'&/FE^3>ZG]=KS8^G#MWAA(LRGZMD?2&/5_,[&_Z9__ %O]]5<;ZP]3>[<W
M.L+@?S7@#_,;[5U/U4^HF#TG'JR.H5LRNI%H+BX!U=)Y]/&8?;^C_P"Y'\Z_
M_@Z_T2U^L_5SI76:B,JH-O\ S,E@#;6D?1]_Y[/^#L_1J:&/EL(J&&.67Z67
M+4LD_P##G&:#RTLLOUF>>*/^K''P_P"![F)Q^B_6ZPO;C]3(+7:-R0 T@_\
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MOIL:UM/^E]C%WE77NO?LW-ZID8>(W&P69DMKOL=8ZS#==0YL.Q:V>E;=C/\
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M]4]/T_YS=ZN/NV_REXZDG8]_TOF_1_[I!?JI8/UJJ^K]N/77U:[[/:Z?L]K
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M!"4      ! _+?LY\T/^ %S[3K)C"5B_.$))300Z      #U    $     $
M      MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    ) %( 10!$ %, 2P!) $X 4P      #W!R:6YT
M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 2P    !  $!+     $  3A"24T$)@      #@
M   _@   .$))300-       $    'CA"24T$&0      !    !XX0DE- _,
M      D           $ .$))32<0       *  $          3A"24T#]0
M    2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M 0!:    !@       0 U     0 M    !@       3A"24T#^       <
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #30    8
M /H   0:    # !% %8 2  M $P ;P!G &\ +0!2 $< 0@    $
M                 0             $&@   /H
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   /H     4F=H=&QO;F<   0:
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   #Z     %)G:'1L;VYG   $&@    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$%       !     (X0DE-! P     #F     !    H    "8   '@
M  !'0   #D0 &  !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@     '_
MVP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4
M$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_
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MNVP:AMN1;8^KU;?Y+;J[;O\ K_\ P;%U0_Q6_5[]F_9RZXYVW_E#>[=O_?\
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M\A[JD[CQ9 3#TF!J>/\ =O8LDN6YGD\L<.:8SXLL>/EN9C_E /FA/^OP^O\
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MFYS-^X;XK_KU_P W@]/"_P#_V3A"24T$(0      70    $!    #P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !< 00!D &\ 8@!E "  4 !H
M &\ = !O ', : !O '  ( !# $, (  R #  ,0 W     0 X0DE-! 8
M  < " $!  $! /_A'=!H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_
M>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK
M8SED(C\^(#QX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z
M>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N-BUC,3,X(#<Y+C$U.3@R-"P@,C Q
M-B\P.2\Q-"TP,3HP.3HP,2 @(" @(" @(CX@/')D9CI21$8@>&UL;G,Z<F1F
M/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C
M(CX@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z9&,](FAT
M=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIX;7 ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(B!X;6QN<SIS=%)E9CTB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@
M>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C945V96YT(R(@>&UL;G,Z:6QL=7-T<F%T;W(](FAT=' Z+R]N
M<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(@>&UL;G,Z>&UP5%!G/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B('AM;&YS.G-T1&EM
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N
M<R,B('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G
M+R(@>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(B!X
M;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P
M+S$N,"\B(&1C.F9O<FUA=#TB:6UA9V4O:G!E9R(@>&UP.DUE=&%D871A1&%T
M93TB,C Q-RTP,RTQ,E0Q-#HP-3HS,2TP-#HP,"(@>&UP.DUO9&EF>41A=&4]
M(C(P,3<M,#,M,3)4,30Z,#4Z,S$M,#0Z,# B('AM<#I#<F5A=&5$871E/2(R
M,#$W+3 R+3$V5#$T.C$P.C S+3 U.C P(B!X;7 Z0W)E871O<E1O;VP](D%D
M;V)E($EL;'5S=')A=&]R($-#(#(P,3<@*$UA8VEN=&]S:"DB('AM<$U-.DEN
M<W1A;F-E240](GAM<"YI:60Z-C!B-C(W-C0M,F(P9"TT-V4S+3EC,F$M-S1E
M-F,T.3-B-68W(B!X;7!-33I$;V-U;65N=$E$/2)A9&]B93ID;V-I9#IP:&]T
M;W-H;W Z930T8C@R8F0M-#=D8RTQ,3=A+6$Y8V,M.#4R,#DR8V4Q8S=B(B!X
M;7!-33I/<FEG:6YA;$1O8W5M96YT240](G5U:60Z-40R,#@Y,C0Y,T)&1$(Q
M,3DQ-$$X-3DP1#,Q-3 X0S@B('AM<$U-.E)E;F1I=&EO;D-L87-S/2)P<F]O
M9CIP9&8B(&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/2)0<FEN="(@>&UP
M5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0](D9A;'-E(B!X;7!44&<Z2&%S5FES
M:6)L951R86YS<&%R96YC>3TB1F%L<V4B('AM<%109SI.4&%G97,](C$B('!D
M9CI0<F]D=6-E<CTB061O8F4@4$1&(&QI8G)A<GD@,3 N,#$B('!H;W1O<VAO
M<#I#;VQO<DUO9&4](C,B('!H;W1O<VAO<#I)0T-0<F]F:6QE/2)S4D="($E%
M0S8Q.38V+3(N,2(^(#QD8SIT:71L93X@/')D9CI!;'0^(#QR9&8Z;&D@>&UL
M.FQA;F<](G@M9&5F875L="(^179O;&5N="!,;V=O(%8S+7-I;7!L93PO<F1F
M.FQI/B \+W)D9CI!;'0^(#PO9&,Z=&ET;&4^(#QX;7!-33I$97)I=F5D1G)O
M;2!S=%)E9CII;G-T86YC94E$/2)X;7 N:6ED.C0V,S@T-&,Q+3@Q-S,M-&4X
M92TY.65C+3(X8C9E,F(U.&(Y9"(@<W12968Z9&]C=6UE;G1)1#TB>&UP+F1I
M9#HP,S)E,F0W9"TV9C,U+31A8C8M83<X.2TY,CAE,F(W-&9B.60B('-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#TB=75I9#HU1#(P.#DR-#DS0D9$0C$Q.3$T
M03@U.3!$,S$U,#A#."(@<W12968Z<F5N9&ET:6]N0VQA<W,](G!R;V]F.G!D
M9B(O/B \>&UP34TZ2&ES=&]R>3X@/')D9CI397$^(#QR9&8Z;&D@<W1%=G0Z
M86-T:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#I&.$8X
M,#-!-#E$,C(V.#$Q.#(R048W,44S,S@R,3 S0R(@<W1%=G0Z=VAE;CTB,C Q
M-RTP,2TS,%0Q-SHQ-3HS,2TP-CHP,"(@<W1%=G0Z<V]F='=A<F5!9V5N=#TB
M061O8F4@26QL=7-T<F%T;W(@0U,V("A-86-I;G1O<V@I(B!S=$5V=#IC:&%N
M9V5D/2(O(B\^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)S879E9"(@<W1%=G0Z
M:6YS=&%N8V5)1#TB>&UP+FEI9#IF-V4Q-# W,"UD86(Y+30T9&(M.&$Q82TX
M-&0R,S%C93<Q86,B('-T179T.G=H96X](C(P,3<M,#(M,394,30Z,3 Z,#,M
M,#4Z,# B('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E($EL;'5S=')A=&]R
M($-#(#(P,3<@*$UA8VEN=&]S:"DB('-T179T.F-H86YG960](B\B+SX@/')D
M9CIL:2!S=$5V=#IA8W1I;VX](F-O;G9E<G1E9"(@<W1%=G0Z<&%R86UE=&5R
M<STB9G)O;2!A<'!L:6-A=&EO;B]P;W-T<V-R:7!T('1O(&EM86=E+V5P<V8B
M+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC
M94E$/2)X;7 N:6ED.C0S8S@Y.6$T+64R-F8M-#)C82TX.&)E+3AF83!A,CDX
M,F(U,"(@<W1%=G0Z=VAE;CTB,C Q-RTP,RTQ,E0Q-#HP-3HR,RTP-#HP,"(@
M<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-#(#(P,3<@
M*$UA8VEN=&]S:"DB('-T179T.F-H86YG960](B\B+SX@/')D9CIL:2!S=$5V
M=#IA8W1I;VX](F-O;G9E<G1E9"(@<W1%=G0Z<&%R86UE=&5R<STB9G)O;2!A
M<'!L:6-A=&EO;B]P;W-T<V-R:7!T('1O(&EM86=E+W!N9R(O/B \<F1F.FQI
M('-T179T.F%C=&EO;CTB9&5R:79E9"(@<W1%=G0Z<&%R86UE=&5R<STB8V]N
M=F5R=&5D(&9R;VT@:6UA9V4O97!S9B!T;R!I;6%G92]P;F<B+SX@/')D9CIL
M:2!S=$5V=#IA8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7 N
M:6ED.C S,F4R9#=D+39F,S4M-&%B-BUA-S@Y+3DR.&4R8C<T9F(Y9"(@<W1%
M=G0Z=VAE;CTB,C Q-RTP,RTQ,E0Q-#HP-3HR,RTP-#HP,"(@<W1%=G0Z<V]F
M='=A<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-#(#(P,3<@*$UA8VEN=&]S
M:"DB('-T179T.F-H86YG960](B\B+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX]
M(G-A=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7 N:6ED.C0V,S@T-&,Q+3@Q
M-S,M-&4X92TY.65C+3(X8C9E,F(U.&(Y9"(@<W1%=G0Z=VAE;CTB,C Q-RTP
M,RTQ,E0Q-#HP-3HS,2TP-#HP,"(@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O
M8F4@4&AO=&]S:&]P($-#(#(P,3<@*$UA8VEN=&]S:"DB('-T179T.F-H86YG
M960](B\B+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](F-O;G9E<G1E9"(@<W1%
M=G0Z<&%R86UE=&5R<STB9G)O;2!I;6%G92]P;F<@=&\@:6UA9V4O:G!E9R(O
M/B \<F1F.FQI('-T179T.F%C=&EO;CTB9&5R:79E9"(@<W1%=G0Z<&%R86UE
M=&5R<STB8V]N=F5R=&5D(&9R;VT@:6UA9V4O<&YG('1O(&EM86=E+VIP96<B
M+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC
M94E$/2)X;7 N:6ED.C8P8C8R-S8T+3)B,&0M-#=E,RTY8S)A+3<T939C-#DS
M8C5F-R(@<W1%=G0Z=VAE;CTB,C Q-RTP,RTQ,E0Q-#HP-3HS,2TP-#HP,"(@
M<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-#(#(P,3<@
M*$UA8VEN=&]S:"DB('-T179T.F-H86YG960](B\B+SX@/"]R9&8Z4V5Q/B \
M+WAM<$U-.DAI<W1O<GD^(#QX;7!44&<Z36%X4&%G95-I>F4@<W1$:6TZ=STB
M-C8N,# P,# P(B!S=$1I;3IH/2(U,2XP,# P,# B('-T1&EM.G5N:70](E!I
M8V%S(B\^(#QX;7!44&<Z4&QA=&5.86UE<SX@/')D9CI397$^(#QR9&8Z;&D^
M0WEA;CPO<F1F.FQI/B \<F1F.FQI/DUA9V5N=&$\+W)D9CIL:3X@/')D9CIL
M:3Y996QL;W<\+W)D9CIL:3X@/')D9CIL:3Y";&%C:SPO<F1F.FQI/B \+W)D
M9CI397$^(#PO>&UP5%!G.E!L871E3F%M97,^(#QX;7!44&<Z4W=A=&-H1W)O
M=7!S/B \<F1F.E-E<3X@/')D9CIL:3X@/')D9CI$97-C<FEP=&EO;B!X;7!'
M.F=R;W5P3F%M93TB1&5F875L="!3=V%T8V@@1W)O=7 B('AM<$<Z9W)O=7!4
M>7!E/2(P(CX@/'AM<$<Z0V]L;W)A;G1S/B \<F1F.E-E<3X@/')D9CIL:2!X
M;7!'.G-W871C:$YA;64](E=H:71E(B!X;7!'.FUO9&4](E)'0B(@>&UP1SIT
M>7!E/2)04D]#15-3(B!X;7!'.G)E9#TB,C4U(B!X;7!'.F=R965N/2(R-34B
M('AM<$<Z8FQU93TB,C4U(B\^(#QR9&8Z;&D@>&UP1SIS=V%T8VA.86UE/2)"
M;&%C:R(@>&UP1SIM;V1E/2)21T(B('AM<$<Z='EP93TB4%)/0T534R(@>&UP
M1SIR960](C,U(B!X;7!'.F=R965N/2(S,2(@>&UP1SIB;'5E/2(S,B(O/B \
M+W)D9CI397$^(#PO>&UP1SI#;VQO<F%N=',^(#PO<F1F.D1E<V-R:7!T:6]N
M/B \+W)D9CIL:3X@/')D9CIL:3X@/')D9CI$97-C<FEP=&EO;B!X;7!'.F=R
M;W5P3F%M93TB159((%)'0B(@>&UP1SIG<F]U<%1Y<&4](C$B/B \>&UP1SI#
M;VQO<F%N=',^(#QR9&8Z4V5Q/B \<F1F.FQI('AM<$<Z<W=A=&-H3F%M93TB
M4$%.5$].12 V-C(B('AM<$<Z;6]D93TB4D="(B!X;7!'.G1Y<&4](E!23T-%
M4U,B('AM<$<Z<F5D/2(S-B(@>&UP1SIG<F5E;CTB-#4B('AM<$<Z8FQU93TB
M,3 U(B\^(#QR9&8Z;&D@>&UP1SIS=V%T8VA.86UE/2)004Y43TY%(#,Q,34@
M0R(@>&UP1SIM;V1E/2)21T(B('AM<$<Z='EP93TB4%)/0T534R(@>&UP1SIR
M960](C,U(B!X;7!'.F=R965N/2(Q.#DB('AM<$<Z8FQU93TB,3DU(B\^(#QR
M9&8Z;&D@>&UP1SIS=V%T8VA.86UE/2)004Y43TY%(#$U."!#(B!X;7!'.FUO
M9&4](E)'0B(@>&UP1SIT>7!E/2)04D]#15-3(B!X;7!'.G)E9#TB,C0S(B!X
M;7!'.F=R965N/2(Q,3$B('AM<$<Z8FQU93TB,S<B+SX@/')D9CIL:2!X;7!'
M.G-W871C:$YA;64](E!!3E1/3D4@,S0P($,B('AM<$<Z;6]D93TB4D="(B!X
M;7!'.G1Y<&4](E!23T-%4U,B('AM<$<Z<F5D/2(P(B!X;7!'.F=R965N/2(Q
M-#@B('AM<$<Z8FQU93TB.30B+SX@/')D9CIL:2!X;7!'.G-W871C:$YA;64]
M(E!!3E1/3D4@0V]O;"!'<F%Y(#$Q($,B('AM<$<Z;6]D93TB4D="(B!X;7!'
M.G1Y<&4](E!23T-%4U,B('AM<$<Z<F5D/2(X-2(@>&UP1SIG<F5E;CTB.#8B
M('AM<$<Z8FQU93TB.3 B+SX@/')D9CIL:2!X;7!'.G-W871C:$YA;64](E!!
M3E1/3D4@,3DS-2!#(&-O<'DB('AM<$<Z;6]D93TB4D="(B!X;7!'.G1Y<&4]
M(E!23T-%4U,B('AM<$<Z<F5D/2(R,#,B('AM<$<Z9W)E96X](C B('AM<$<Z
M8FQU93TB-C$B+SX@/')D9CIL:2!X;7!'.G-W871C:$YA;64](E!!3E1/3D4@
M,3$V($,@(B!X;7!'.FUO9&4](E)'0B(@>&UP1SIT>7!E/2)04D]#15-3(B!X
M;7!'.G)E9#TB,C4U(B!X;7!'.F=R965N/2(R,#8B('AM<$<Z8FQU93TB,"(O
M/B \<F1F.FQI('AM<$<Z<W=A=&-H3F%M93TB4$%.5$].12 S.# @0R!C;W!Y
M(B!X;7!'.FUO9&4](E)'0B(@>&UP1SIT>7!E/2)04D]#15-3(B!X;7!'.G)E
M9#TB,C$Y(B!X;7!'.F=R965N/2(R,C@B('AM<$<Z8FQU93TB-C@B+SX@/"]R
M9&8Z4V5Q/B \+WAM<$<Z0V]L;W)A;G1S/B \+W)D9CI$97-C<FEP=&EO;CX@
M/"]R9&8Z;&D^(#PO<F1F.E-E<3X@/"]X;7!44&<Z4W=A=&-H1W)O=7!S/B \
M+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B \+W@Z>&UP;65T83X@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2)W(C\^_^(,6$E#
M0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8
M,0  86-S<$U31E0     245#('-21T(               $  /;6  $
MTRU(4" @
M           18W!R=    5     S9&5S8P   80   !L=W1P=    ?     4
M8FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D
M   49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P
M ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E12
M0P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y
M<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M        $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V
M,3DV-BTR+C$
M                 %A96B        #S40 !     1;,6%E:(
M          !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4
M !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO
M+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M
M9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ
M  !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@
M  !,"58 4    %<?YVUE87,          0                        */
M     G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ",
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MA!5U4T2T8/&C)18W".+CI&2%M287_]H # ,! 0(1 Q$   "?P
M           69Z.''*WPQP!>G1R[&FAV2
M!_/K>):\=OA.ILEYSKI,V3B#W6]2^[^?3^_5(<;JR#T>AYH\?KVR4=[QMW%7
MWEOR@                            69Z.''*WPQP!>G1R[&FAV2
M           !#ISO6_+O;U@2^L%V/VV/[0      *;X..$.F'@PMT2_;<Q+*
M5^%EZ]&2EE9&@L /HQJWB=NWK=Y1L+B6C9!H=807IN.9CW_6K+6PC&FR&W;N
MVWR;SG.@                           69Z.''*WPQP!>G1R[&FAV2
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M^YA07H]3\78           !97HXX93_EMCN_,EHCNR3B>\  "S/1PXY6^&.
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M3ZO7"N]?Z!QE]^,:@"8%@NQP_<Z5P  ;):G[>H7IY>[X\W*#)L958F6;*^
M )YVMEKE-8:GP  -:%;P%'M^>FN-PPLO6H67K</-6)<YV*O_ $/]5(M%>N'\
MA[HXQUT=?DN#\B-@57E\\,:9_P!7.+?J%X56]A_I>2MV'"%YWG3;U?*OS0]!
MMVH]9YUVL<Z]7T)<7&-]>CI"7OIY]^O9X3)&O^S^/V;P=NHV\1^0L5W<Q[;V
MC=FC0?)4+/8"LPX\\5L    3YM:+;*"P].X46'R\GC=;'_R_H>D>3GUX-',B
M>@>7F!'#RM"\]/:*G@;ZL:RW1^U1NE)Y_G-BVSI6DK(46    /2/)SZ;>H=X
MVBT[WBS/1PXY6^&. +TZ.78TT.R0!&MRU"<^O9ZH?D    EV8.L4WS7BT <9
M??C&H _1^0  "=/KE:I8.%+!!DV,JL3+-E?   $\[6RURFL-3X  \XD*M$ T
MV^=%#PE8KBCY:X(R4K4++Q_OKWDC7/O-WU[]@*X@+JX1,B#$N0Y3>"\W[ *C
M<!3OSTZ=H+<2+;3_ *E:ZHK8L"^\AZ%Y$[._SJ>T9P^/-8[*[7D)<?&-V68X
MV@E(:K_;*Q_1PJW#EYYZN'LO@[-3%WC_ &+P=G*SW-H5(Y_@N+J_9NFO-HDC
MXGF[;[>,5C,\!#RSM7/Y?H9!1G=UH=)<@^B^3GS2]MJ1I+R%& =$[5BY2&L7
M3 '.;VJID?O)T0!T:]5+GO\ <92\1W.%>@\[$58#]$AO%LQ(<Q=,WWYN6G>]
MQL5/,\#Y_P"K@!L1JWLZGNFE]K77^V9Z.''*WPQP!>G1R[&FAV2!XY[^KDV;
ML8_\-D>H?HEXX-L4KG"M@OGS\HYV58:#OL35K3[N(K77^]7/2R_YMU[U#C+[
M\8U 'U?B1?BJ9V1U/W:O;CX(]&48?\ &[+'TGTMM2+OHRR-%:F+M'Q&,X5WS
M+V< )9V$[![-']HWSXUEMIM-]X  CW^OY\:;_GSC2X(B;KT7,W%'RUB6RS1+
M?OWL+]ONA[A_(;-Z \T^'5O,^V"B7   ?-^=L<^K?1B)!2?KA;'FFOUX/7_2
M-]GJ.7/EAE[OI_'U=UKUPKR$N/C&RQ=3_MGGO0-GP (*&Q]4BC9I@ )MVO5G
ME]8,L8 @';,U&,1E^# Z$FK]PDB8GFHY65H;GF;14X"19BN9Z'FK=Q'DGNZ^
M1%O'CNS^_B,GX?OZUFD>0AR1-WL>8WRW2!-^UXM$NK!UB &K6Y>#F2;>4?SS
MU< .BQJO<I"&+YBS/1PXY6^&. +TZ.78TT.R0(I6:8""9L?5 )-^(9R?SK+;
M@!$-SE781.PU7 F5X$LDSW 5F'&7WXQJ )J^OUFF(X(L@$&W8JK1*<W5X#-J
MO>KK':49  Y&.\..\99?I ZS>DV0<S8#T@  "Q/?683- ^.M#U+R378B5N"(
MFZ]%S.K7>O-.D3Z9YJ^WG'[8J?QZ/.I&4O?XOU@   :S8?9J"7B?[U^60MY_
M4;Z*[ >?T/WZRY4_4O\ B.O'*6D]>0FR+'FR,KW5'[7@ <H_=.@8#V7R"L</
MWKX:,Y%]@\'8 -15XCN89N!1@)1.'9V>_K3;;1[^/(_W?QYX+)=0](\G/KP:
M.9$] \O.-EEF$Y\FS]0 F!X+L4V77NT:>KW&\QS;VC@;!:Q[.JWI??OH_  $
M*O8&L0Z\[UP"3CB&<G[ZRVZS/1PXY6^&. +TZ.78TT.R0.<3M;2]!N2XD#J3
M:<7O:%3O> /!)/IY"^\F._Y?H;CZ')=-G4.\#C+[\8U '7+T?R'D[#]X&K^X
M>#EK[D40#)J([NN=H]D0#D8[PX[QEE^D#K-Z39!S-@/2   -1.7M#(PNC6IE
M6QO;:[%25=B)6X(B;C[_ %MVLP?V=R#L K/JZ?.GUZ]OCNX    #657]HX$6
M!_Z$/GKGKNJLQMW5F*OZ4UJ]H^T?\.-?R#K-<G&'FR:6_?CW6"R* .-COIC:
MB]GX     -TN/Y/IAZCW<08MC*K$TS97P.B=JQ<I#6+ICG';64O01DR)']_Q
MU=-++_G;6_7%[S#!0&]EZD!*NPO/SNM;[6  -1%YCN8=M_1@-PE$D>G)J%>;
M,]'#CE;X8X O3HY=C30[) Y5.Y]!UVVGQ@    #*J%[^M]I#D,<9??C&H [+
MVA&2OJ_ &&4_YN3)NSCX#)J([NN=H]D0#D8[PX[QEE^D#K-Z39!S-@/2   (
MLNROQ5U ?,;MK\/+W!&2M=BI&NQ$M&2^VF]-HWBP]2#3F][&ZI[0     (Y6
M+/IA%$UQ^OEW5F*O*M0EUUR/O+-OSCKWW+_BSK'HJTEC7/Z;;I<-;W@#C-;\
M8U_      -L])D.H#I[>AK@M?BY6VYM" D68KF9Z^M5LY$V\>/+5[N(W-4&2
MZ9VHMX$5'-$!!%V0J@$M;"-AG):ZVD  :TK=X>6)N50P-N-'D.GOI_>K,]'#
MCE;X8X O3HY=C30[) Y0&ZN/\%K'Y0    ![-X.SL!:+9&'&7WXQJ .S1H/D
MH 893_FY,F[./@,FHCNZYVCV1 .1CO#CO&67Z0.LWI-D',V ](  '\_WA"&V
ML_G1Q'^8&>ZY&2-?B)>X(R5KL5(Q<?N1]$I<N'[?-FU[LX      ^3CW0+M*
MOZ%,2\59BNNN1]W5R&NZ#C?Y_7K^6WY_H%\2]N>,-H)46L'UE '(GWBQWC?+
M=(_1+@P?8:_U_H   S5KWJE)8<G@.7SN'1=3MUCQZ1Y.<X'7>TP-MDZF!T&]
M8+?)-Q--C01DR(YQVUE, VY4>1Z>VG]Y  $9C+L'S_MFZB!(DQ9,=$35JY69
MZ.''*WPQP!>G1R[&FAV2!S(=O:/IUO<:!)LQ#.9*Q/<   /4?%V3%L$60<9?
M?C&H [-&@^2@!AE/^;DR;LX^ R:B.[KG:/9$ Y&.\..\99?I ZS>DV0<S8#T
M@  >,S>-X5VT7\]N,WS$V1K<7)UR,D:_$2]P1DK'&^UGTEZS&FN3O>XSN
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MW1?[@@#\'-<VTI.CW(D6 ,[*YZLF8?OPQL'FQ(F_.!('QC+]$_5BY5+A^@"
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M=L!%7=78R[*_&>0;2ZF91?TK_%F2U@?;D
M                      #1YG+YLQ_<^_-FTN<UXAKG;/-]9_?4H[LK$7(5
M:,]FU^5V4E_Y4^G_ -?[V     8M3/1RX=QJ'BU,]&^+X;_37<?\C=V[NKL9
M=E?C+KKD=A']._G7)5^SFG^?-/R*
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M])=U7Q[W%NNN1UTU:,NNJ1OF7U TXDJ_;_5BK=?8
M    /&)#KY,F[./>P%HMD8 :F+O'PF-@ZOTSM1;Q#+SY6A,TP'90  !$FS=7
ML.I[S1_,G1'3VT_O.5<+Z (&.RE3VSTB0DSXBG  !#+SY6KSZ.4P'!5C CEY
M6AH_^38?H::N7$ 0R\^5J\^CE,!P58P  (_N>_G/'PSIH=0>NU6EWR%F>CUV
MFG:34I/^^$O!7L3>"Y<>^.XZKV>S]M\V=Y5VP])S5GW2ADWQZ#,E^'S;E.?S
M_.T#)C7/)\QW^2/['^@TCJNFK1EUU2-^SG4]F_\ 5E\T,V\C>
M              #QB0Z^3)NSCWL!:+9& &IB[Q\)C8.K],[46\0R\^5H3-,!
MV4  "B=GYRE]T:!TSM1;Q&=R[!^6^SKFTZ]V@"!CLI4]L](D),^(IP  0R\^
M5J\^CE,!P58P(Y>5H:/_ )-A^AIJY<0!#+SY6KSZ.4P'!5C   ^#L\\0W:OY
M%:T;YAVTN^0LST>NTT[;_P"66V^-FM7G/6SPL5LIZR^[VVDFK:Y66VN-GM?]
MG*'U6#^?YVBO0GOEW?RG?7?.K2S*=TU:,NNJ1MU5*)R[_H!T8V<_2?"0
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M9VHMXAEY\K4?_)T1LSJ'N &T"G^[=SCR4YRVU=,ZL>EU^^[C^@#2%D.+A5[
MUCJ(Z=WN!CLI4]8UO\&:=?\ 4 )UNN%KR'B^Z&7GRM7GT<I@."K&!'+RM#1_
M\FP_0TU<N( AEY\K5Y]'*8#@JQ@     #'2E9.U/ZS;C:Z,19/Q/QW8JS2?=
M[#ABZ>@TK\NZNQEUUZ-]/]-6RNV'PKF-N;@/+W?S ->M<6
M              /&)#KY,F[./>P%HMD8 :F+O'PF-@ZOTSM1;Q#+SY6H9>?*
MT !( QE+[FZ#)8(V3RSN];K6 !\7+\XWV^6-^N=H_D.%CL!68LN9($ #K-Z3
M9!S-@/3#+SY6KSZ.4P'!5C CEY6AH_\ DV'Z&FKEQ $,O/E:O/HY3 <%6,
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M,(\@$K6[[J$$,\%I'0(J)NMWTF1%R1:-<]6N+6[J/ZP;.B80&5%$J6")EM'
MK!H2*,,*8&!!$,#(24"AI&MSWZ,,8X&<\3[3/D3I91*:W91*4MS05\UJ:\KI
M9A'D85=;LNH1)3>"S[H$#-:WK29?EXKNNT;T^MH74,= U=M$A&MJWO8&KK^*
M>P2T\=64<J%<(1T# \X' @8'E P/*,%690;<<4U0]'H0:1!965%>/]BK) *F
M$>!')CC#0*+*4CASG#.N2X[<KEJKL-NZZ#WZ7+09++9X6:0DFM7042@$)4/B
MJBCP6X4JDUXZWH)2&0(*F1B9E&4P5E*T/DP5$B=*#$#D6?1_WSCUO0N>C+Q;
M5/DH/+5Y+4V^VZJJJJN&S"]6('K>5/D8;L%?-:FO*Z6F(R*,_5_*E2L[>!&4
M*TE6E.4Y:7+(R/,SB<!VI27=6 <J(O'5P^P-6][ U=?Q3V%GTC]TLW,5:G"_
M!@><# \X' @8'E&(C=I0K+0['.3:J4K*IY;/]FX4,-8*&Y"%A#ASG!LWR@V;
MABW-<5LG1;.XS?NDTN^*J::Z7,DS0U[@"#I!"[2Z 'IF3I9E<_<)^MVT?U<Z
M(M0C^K&KI.<J9.Y:FX'#%E@95.+6]1J="+Q6W-UE'GK<L*D5D05\UJ:\KHR
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M)30$,DW4N-UMWT&[B&C4&C4&3,&S<I2V@V@(Y<FGZKR6G5_Y*V%BI!7@JZ1
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MSH?ZZ0<3BL[\6WB^$N"Q\7N\UQ-%PBME<+C@F0:O%. X=+$;SP+NVS;H;\#
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MP6/B]WFO\%Y>QKE_KNC]0S#/[[->:(>1_P #_]H " $#  $% /PT3P:A^/\
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MT).%TY.BC@*(IDQ(-")4RJ1"$Y&$"NF0@=85>I W43,4U2JI@3P:A^/086D
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MF+*P[4H41C0Q,Y!4U^:"QF"QF"IJ"YCE  \JH+F/RS*FH)G.4$SD #\X '@
M?E!4U!4USA#7%)$4\#\R"&3+*TW--LBQC0QWP'VO[!MMC(N8^0&&NZYNCY;O
MXLW/]CLAM#ITDF$MY??[=EX%CCIJJHJV2]^Y:05?3JK\2/V2UKTS63<[,9^<
M%\+M-FPMFKFW"<UW+D:(""L.E=P<QF1\.\2HN]=ZVMA+:[K._3>O-=0[#$[,
M;(?"6Z.U3N\V8W*V/K<?^/-;<?R'P;U>_H/9Q26EM9<BQQ[.&^/<#"=PM=SM
MU[-OCW\-[-2<:KQ;8>Y!=3;BR!MG<AE7AMY'5E_V&[#I0OZ;<>XOEJ)91G$S
M%-%)<Q  \%S'*+TWJ;EB;8/NXSENB]2YB<IE34$SD%37YH+&8L)MPYO9$!N7
M80SU;;8O18+)/'%0]ZE:4!/5;"F5N6J S3+M)DIH+U;RO, ?G  \ #\H*FH*
MFN<6GNH[K/ORP%[VID+:V-UGZ:^%7]-L#[7L.]F7&V%M2D<"%_3J/MV ^;5>
MRZ<O="/Y(6RC<5Q6)9I87'21U,.Z6<NBYK(7:M/<IL7FM=KU-^3<[.X&Z].G
MB5_LCN$POKR(U4+>;W:7=N)7A[*T-WKE6$N5M/[E#)W)L<M+C_QYK;C^0]>H
M,W7CF(EL:JJJZNQZ:W<_.,]W\=555=7'TLN81U_61CJR_P"PW8=*%_3;BN[=
M%KV5MK<:Z3JO'<$J:@J:@N8@ ?E&Y=D0+<&ZQ8SS@N8@N8G*:12;43>$>P%D
M[?H#%[;!PMQ) T5T=)<"9E/L<X;Y !YE[7N5&%8VK>N(ZF[4T[N-]<J 'E.0
M _*"IJ"IKG&W#E+78F[\7+MLR+Q6^:#3;S#:=N,?+.6C?$?\+MJ"-T+-0E@/
MA@OKRVZEW1HM%T/YT;=/3+6I:#:MOB!BC9XA=K!/#&^J5N?]-059S9' &+#:
M8J9%O?$G(FT-TF??"U<;_P!B1_JSN)Z]--DY\[MOG7J1LH:+];AFO3BXD?ZZ
M;?\ '4[[A9UA,G6FFJNK!;IQ<P\J$>UW3"[<+*(.KIJ]K5PIV7/2K7&:J9=*
MU-RK)/O7:[SM<^WQETVW$A.]O1<?^/-;<?R'ID+?!E8U6.R6R#N%E7?C2FFJ
MNK:WZ;.NYC6M!@%A+85*N'B5BS=M/W$.F:LI<)MOIBO&V+RT;;B76@X=NC+E
M,SCPXXB1(ZIG<1NF=S;O\AU=)&RYD,R>FXS=QG; @8@(FO3UWA,VEW38W9=E
MW_J)</[1B+UVY^3UY-<<>EU_V!QY^T8C[1B-J';1_P"85F^+=\R+K6G<6,\H
M+F.<%34%347PNR4LS: XL'UA2+&?RP6,\XPHPBR%SPNAMZ[0>,N!*/Q'21-2
M)[A.Q(Q;E@/9D.^VSLE*)2B4H9%SUQL"MYQIK@) #\H*FH*FN<;=6155_K <
M/53Y/"O'(C7IB]NI"1V/P=2QM\(N/-^->F)R5,7=P/CJ8,1Y7UP;UZ9K)N=F
M,_-+^7A;6/ED+AOIR71?^F%N-JYE[E4UVR@LILNARHC,;.7V1KGRXR;UZ?79
MN;#79O!NC[7%G-R.SEVK4OZQMS->FVRS.9"8#1<?^/-;<?R'IU4V4)AD8[Z]
M-CMV(>2-].#J>MO9%7+?Z])]DD:_?<73,[:[8I9^O4V;=#9M6[==M17&0]Q#
M7-7^Y.NW']//L+GW!1+4V[N$^5NX+\+F.4%C/*"YCG!4U&ZC<T4DRY3G*8(T
M;6.V%=W<CNUC-C#97$.T?8[B>V;:;/%FWLLC<S':YDI1335742)<H;"BI()Q
MNN(JN% !^4%34;:-^YV>R5X=TJ\)B_&XEHWD%3=*_CY9QN8\V+X-]2Q9.^^U
M]KTJ=V!6QF?%P&*U[H,3*.P+JQ9R)TLY=%S60NU:>Y38O-:Z.IZR<^4>#.O2
MI8CS6'G&_->L:R6UOKM9XHE\T<[RA0H0*</538:IJ,LZ]+'>D=E9OQ<?^/-;
M<?R'IU)MX!KF;G^NS+CZ3QOVU^#*>RB7D?C:. ,6&TV#;NBVBW3N+"JTZ=8O
M$+7>AM:2NYM?:X5?W)US5_N3KMQ_3S[#=\NW4V+-"G9"G"QF"YCE!8SR@N8Y
MQN%O&IU9*QMN[?MT]Q?(W'+':TV*5FNSW-=NUGYW6E>#-=+ =I(ER@F3YP1(
MSJFAS,)PZ>?H- @#\H3E$P4,8S7:"OG83@<BZ==#B[3I[G;6UMV?3JH\2/<V
M]NO339.?.[;YCJ/LGI7[W%="Q8P<,;:&*)?"O"*.JS<Q@A@]KTH%O2JOE7Q;
M[MMD^YFU9KL'KYUO;M$7'_CS6W'\AZ;MKE&=>YCVF"KM$86;/$2)%4TEKN.?
M3SUPJ_N3KFK_ ')UVX_IY]ANG7)K>>4A8S!8S!8S!<QR@L9Y1?M<J<E[F$Q7
M==![[7>WRR=N?%[M=\_;\)O]IDR?.")&=4R)&7(H4YPFEQ I #P /RC9:NC4
MX+1< @8@(G:;%WU7]-V?$B>:>!6O3-9-SLQGYD3>ANXYV&?3T<5R'MIL,8D_
M[7[BNG5A(GI\3]>DR=A$G?SBWC7279^U_KL1DC1_=DBX_P#'FMN/Y#TW/$BE
M$W&^TQQ_L-V6XY]//7"K^Y.N:O\ <G7;C^GGQC#!%P;XO,=^.L ?G!8S!8S!
M8S!<QRAT&!#CFZ7W;^+N1Q]L?($54AN"8C"XB90$2,N10IS@B1YP3)PJDJR=
M0 \;.#_K;F5W!F-;<>SN6NE/Y9U-7I3'2]6O]I-<./M)KAQ]I-<./M)KAQ]I
M-<./M)KAQ]I-<./M)KAQMW=.L[,'<Q]=[#$FK#_<.TLY=%S60NUU%F<S84MM
M37ID<2/DIA5IU*EK35Q-K[78XRB(8J;D/%U162:=;C"37IC+4COO<FBX_P#'
MFMN/Y#TW\;<&+;[K&N'G3?+F8V,OVDUPX^TFN''VDUPX^TFN''VDUPX^TFN'
M'VDUPX^TFN'%CNEH?-I+U]EN.?3SUPJ_N3KFK_<G7;C^GGQY&..IHV!==/YD
M$N8@ ?G!8S!8S!8S#5MD[[KWLQ;Q]9^*F.W;[SF-8%Y,8RA3G!$CS@F3@D2Y
MP;0Y*2:&+515@.[JVCF+P=29CF-9;<<UZ<3/!(R1P[X;J7LM!8U)XNJ,Q*^9
M^*>MSK^W*NZR-,;[&NK)B_EL+<M2S]MM,H+'I&2V.;M:K@8KJTIJJHJV*]T]
M#SIL'P7,N8P+-,#=+ST7MQ#+C7I8\7C5N\6HN/\ QYK;C^0].K QU,IUQ->E
MQSR1*$;AN7<ZWEFF*WG"@NU![3<<^GGKA5_<G7-7^Y.NVR;+'=N_CS_4Y)&'
MRP#,R2"%_+!<Q  _."QF"QF-@+%#YE;KG^ X$%)=*#=JU)^S]VR9."1+G!$C
M!(E%Q4V:"[K'+52+>/@ZB7"0SE9@YKBSE!=_#F^.W-O:XEYZ-[2JJFBG/G?H
MPLPO3<W<]<CL_P"ZVS'O\*EA*$E62E]*X+WVB:5_K.WIM,[[#7=X>EDQ'J?F
M0G!U*^"!RP>56MJKKW(L=<+ 3J>[0/A*M'E%C=?Q.77"@-=-RIWQ-N3%9+W/
M=XO(7<F6]<6L<;A9<9 V)LPR,=K-1<?^/-;<?R'INEX:@9V82*B6I(BGI;ZX
M#UM2]]L+J$,?<J6^ ."9!TSAW><)<#DS<FW9,DMR5X[0>]I<O;]7;2W;MK?>
MW/9[CGT\]<*O[DZY]HU3<SKUV/M]BQEDK%#;M6V@ G9"]2GMP6@(;/6X0_-R
MG'S@W(OZ6F87 9IR^"-R@N8@ ?G!8S&PU:=IM"VO^#NP$F>%G$2)<X(D8)$H
M)$HR(1Y%TQB&_P#^LX! PQ@]\3:]5< ,B>"SVYUN"V%)'-_7=O/)]ZL]LT\B
MR6NSKO>W"P,5T=6)+R1P=4)B13:?+7AV?<2/],=O_@S+Q-MGFYCGEIBM=W"Z
M_79!AB#"; .U(<PMM1I<?^/-;<?R'KU(FUX<M1<;@L=GCF=C65!W]=V\!*NY
MN>;A%\R5555=6FU[NQWSVU;AV ODP<E[,=EN.?3SUPJ_N3KOH6G.VBW3.+I4
M?IY\&X@0J4L-C,78(3)N$N8@$;E!<Q  _.-D>\(:!>+_  !! P0R64-66F?!
M$C!(E!(E!,GRC(!&_<6DLX6]>72X<E,;[19:V7W.-J:_6VU<CL  !C(VQIL2
M'6>>X=[[$NK+S;MX-F?$K_<C<)XMT/:ZL]N7VCRPQ"O[A3=OL$='5W"K;)^P
MF)9-0UN/_'FMN/Y#U>C,:EQFAO"[(]R,#7)V.RCL8.3*E93T\@DD.RW'/IYZ
MX5?W)UZIW"E5<S6XNE1^GGP98H-3EQF,Q<Q'FJH 0LY3+F(!&Y07,1C[>!4L
M9>5LN-&>#<[??!R]#P_V\]M@S^6^A(E!(ES@F3Y01(Q>4A37:#!1 J>F8G%<
MFVEOKQ,;<%Z7U<*'KSV"O;CH[N'#?:\S8SI5-LS83QOP4'XJJ::Z=UG$N>%N
M>.O2UXDU6YQJX\I\0L>,T;9YX=,WDS94^]6*]K;.7APNV/L^LS36W/LOXF;>
M1?@N/_'FMN/Y#X%)-3EE.W%.F7MG=@YDMA?E-A\Y.'%_"+*O,MR[;/39V@Q^
M.@  E@>SW'/IYZX5?W)UN#;]EW68VZGL17[PL=?!9^R-X,@'IL18.7SP(PMX
M%=+*+B2ZT0ZV5\]*54.M'J;ZV$+.4RYB 1N4%S$;,>4@-P[3=OU#^> 66F9^
MV<3&-Y#DB7."9/E!$C!(E%YZ)E+-;)C%$>V>/87(M7;&\;8O3T[FUU>$=W=)
MMCB=&^TFMY#$Z4W"M&-8_;,6VGC<.  "6![#+#;(P=SA>'V^6T)'V^6T)'V^
M6T)%I;46]L7;/L;UXUX^Y((=WNFJVQ+F&''TF%C#1@ATE-K0S=L^EIV_VF+C
MOMGX&8J&.(V4+'RO_*;;7C_E-MKQ_P IMM>"FUCMPD#7$Y6NV7FB7SV%]KN^
M@KWZ3_%!1'^TFMY#(Z3_ !03A[%;#.U[8@=OMY ::-P_\IMM>/\ E-MKQ_RF
MVUX_Y3;:_"[&HVGXU?\ E-MKQ_RFVUX_Y3;:\-[;'V\VDO\ #D5M$[=&4BDZ
M^EEV[ET9)Z4G!D$2U/3J[65LC=J[,6@L6V>+</M]5;S+,[WOAOR74T,2JBH(
M6<IES$ C<HQ[OH[\=[MV7N\S+\VP[7?3W+2^!6,%555=6U(@3.W7)DX(D8)$
MH)DXRG.4H6._3P6IG2A?^2[R-J:S"6=[S</QM3IK!&YP$+.4RYB 1N4;8V>@
MV*UP"!\BJD>SS)R^L]@Y8+,W+J[&<>0T;2++K*VY(D8)$H)DX)DXW%'(&W[(
M;8MB!<><)/\ R7)JSX%^+%+)0TGG#<&92G2Z&Q40%!&YP$+.4RYB 1N4;96Y
MJ)9(0@?(JI'L<J,K;'896;W.-RN[>Y1?+3"&U@EL<9R9."9."9."9.%ZT_\
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MC]IC:>S5DUUM[B2+6I36ZMV6M,Z5I6E33^07.U-L7\-KLZ%=9Y975$4<99B
M.3C.0SQ/L[[N-E?ZA>"H^E7 >.V!XTB&K-,.5C".$:XP[=K>TUS<VI-1 #U=
MNM#4:L$>K%494<J7-!K,3G@D#!RP<L&P^[/L#M':[JVJ\D,>K;Q,14":[D*6
ML!(T==,E>#%O>_>E]X.SMB6YH3;V<;7]S3*J.Y:WMXV.?2C>Y49&C5($3;>L
M-L]H+@9GZ9?/$A:G FSULB%!S"L[\3%QIC79GW&]FF* 4:XL8;MQ2E")+M9W
MUAJ@ZVMK5J:U)KU%E]VVP(8:UU4V?:(M3I-%A KEGA$O_NS[/SHIJ!)LZS<
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M.F0;C6ARU37N]CM^!*)<KU<E/^(@Z)/*R9?W>YMO[0GO.X[*^Q_K'W]ILVU
MZZ5Z5.A1I9FXE506;D!Q<)LJ2O9?9RFULAP-&C'7N#P%[F4M,30'4:-#D@P2
M!N$@8) Q-]XNU+:G:/M H,51G%8(U8@.$&Y<&=B#1XQ;Y!E-=UG=@$ J2<@
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M_6159!SQGI@>Q9SZW$5Y8W*2VKBJLI!![XX1H(T@Y$5WEUL]E'TL#7A8^ED
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M0:P2^NU65ETI E9+B0<%4A1V%<B0!PXM-G6,"Q65O$L<:***D:*%1%' JJ
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MXC&Q4 \ZA3S$;^P_V]/TT^]V$Q&EI![J&1?/[^C<M-LHGP-[;C6/]I#1&_\
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M1- P&AE/I7&=#H.@@BE(]H;+N1)"=(T,A]2ZZ58<7#I!((/<7EE<+&HJ230
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M''PD>?OXKNRN'BNHS564T(/./-&@C(Y8CM.U$)5\AU\8J#RR1C,'C* @\"#
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M *M? 2YX:M0^3C9:2O1Y>TMFBY'-A;7STR&711C4T&5-) )SP<\L$ X.>/N
M@,K+3M?LIZJ:'X.\ADU>9M758<*DC%W%6C7$L<8]UUA\R,UY.XBXL;N2&<:&
M1F1O"I!P%>^2X0<$J!OREU'/?8X'TG8ENY]:SIX]?'\.Q_/']GBEKLVTCY2'
M<][IJ/"#ADN=LR)"?2Q4B%.+H!6(]D3@DFI/<9;78^T3# [ZS#4C<%J 5Z:-
M3( 94K08_?G_ (-O^RQ^_/\ P;?]EC]^?^#;_LL7%_>S&2[E<L[&@J3IR
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MQ_$4?S)_:8_B*/YD_M,;/VP^VDE6!B=41%2:JRZ=<TTUT8VY_<_]1%N=I_\
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MAK6S)*EPPH5FN&#10$$%0LTP.M"H:.*)0L2@  9  "@ '  ,J8 )P,\L#/+
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M:*M !HP,\#/ SP,\; @U:,MG%7@Z112W%Z8GEX\\*B"KDT PL8S<YL>,^@-
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M=Y;^S7QC>7*\4C>,[Q;:Y- NAM(IQ'SL5^E)X<'JR7;D%!X33S*XDF= M'(
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MWU>S_:'7GR'12\4CZ4G)UA9;@$GI-+(%%(SCOX&!@R6^3<7!WO0P58$,.#<
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M8Q;^V]ZVY9^W_-Q)U*J=:E:@\%>(CCQ\5%X&_I8^*B\#?TL?%1>!OZ6/BHO
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MVQ&BQF&R-QPR$  5551$VRWI>Z&\RFXKHK".3CVH6NN-R'H&4ZMNAXQ%MZ+
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M)LG#9.&Y$\*[#PW;MWH>#ZZ_7VDQ$3<9M*3!+PY9 )S,DJ_X*N(B%]455-B
MT43 E$Q+@0$*[E147BBHJ;MNG6T;=)HIFIM%BRD*FBJ&<$[A3K?WMIXN5YO(
M%!4W(FXN)".\D[S(-1X%>4;$^I7!,5U1KWV6C& &55$,<!SFM;<+[NR*PQB/
M;RD151%N07AS<H]VMZ;,KO&CUGZ48,3$PKID@4L,BT4=?-K3C(:]HR!9$3$8
MZ^UN2#(DD-N#!-XD*:US=[2WVL>I>$Z8TV1Y/2890V>;Y'5XY#M\IR*:U J*
M2O>LY$<9,V2^ZA$@[T99$WG5!ILS'OM/.JO':_M<HZ;,M2BS!UAC[[(TIU3F
M5E,[*E.M\SLCVMY_%J.P A4&6;28[S#ZY#[NA6GN:W)6.,].^GMMIKIQ#^_;
MX=!<Y_ENH,QZ8KKSHOV/CV5^(BX"-H-;70F.7[QS%W-'] ,*$DR75W4+&,%@
M2_%W93-0U>VD>+99#.98175JL;JB?L)9)]Q%C.%X$VP#2?!8'DO"M,\,QG L
M3KE4".'CN)4T*AIH[KC;;(.O-P(#:&:"/.>\MW'NZWZ 7ALL0-7]+\SP(9T@
M3(*BQR&BF0:6^% !PNVH+ER/-;W">YR./K2\"Y-A.65<JDRG#L@N<5R6EF@K
M4RHR#'K&34W-7+;7BW*@6,1QIP?0,%3NB8$0&!(0D*J)"0KO$A)-RH2*F]%3
M:MT?U0R9K_>NT/QVNJLRC6TML;757#*\6ZVFU6J>V<1ZWG$V#4;(^S0CC69!
M(<1MJ='1>\RS5/5/+*7!=/<%I9>099EF02QAU5-50Q3M'WW-Q.///.$+3##0
MN2),AP&60-TP LSUO=8G5&G=3':P+1?%9Z\DG'],J"9.>J7K*.$B3'9R+)IT
M^3:V*-FX+4F8K &;3+2]YJYU0Y!7'&M.HG.HF,X8](93>]IQI"=O5':5[QMB
MXVQ<Z@7EQ%D"*J#A4S)+Q%-VV>>XS*/8.=WF!^[/%_9R#W>F3JNJZUTJS*,4
MN]!LSL66E&)$NL3LK#.L"":8@C9V5]59/>BV1$KA,4_+]RV.[NYWT :@W80[
MQ+:WU8T \?=9;:MX4N*T[J9@->9=DI6%9(AC?Q(Z=JZ^S(LW%40C(B][DFIN
MJV9XYI[I_B%>=IDN799:Q::CJ(8F#0')FS'&VU>E270989#F>DR' :: W#$5
MI<IQ:ZJLDQG)*J!>X_D%%/BVM+>4MK%:G5EM4V<%U^'85MA#?!UEYHS;=;-"
M%5147S7KQ^AEU0_$AG'>=)7TFM!OC3Q7O.K7Z36O/QIY5WG0@]$?:D-!T==-
M,0W&30P&3 T;PV#-84A541V+,CN-&GA$P5%XIYAK?+5P6D=H*:LYB;)Q%6[R
M_':86^4$)4)U9_(A> %+F7<B*NTR.GAD1)+*;OJNLDVG^5LG'A_"B[)Q\_V-
MD5%X^KLBHOIILG';574^XKNUQ'I2;U"S2(;C;91#S;.[6VPO3J&_'4=R$E#:
M6]K').#4BJ;5..[^X;O&+^$S9461U%E0W5=(158L*FWAO5]E"?1%159E0Y!M
MEN7[DEVU(TMLD>.3@.:Y'BR2) "#DZ)46DF)7V>X!$%;M*]MJ0"BB(0.HJ(B
M;)PW(GA78?6[MV[T/!]O9.'#9.'U/0VF @\D>R!JTC__ ,I3&3];C-:<7=Z"
M*FVDMRV;('4ZF8'9@<DE&.!P,IJI0F^8N-$+ DUO)4,50=_%/#WL_4[#JLK#
M53I2EVVJU*S'95Z?<:;OP&8^K>/1D%%+F;I*Z+>"B(3CAT2,@G,]WF$]0&B&
M0E09SA,_M19D>,/4634DGE;N\0RRM8D15N,7R&&BLRH_: :>M=9-J0TTZWC^
M-V64TNB'4>Y%BQ;[1?.KB/6!=7*M\KS^E636*PZW/:R8X!FU$:(+J. EV\06
MT!]WN$9D(  J1$2H(B(IO(B)=R(*(F]57:XQO#\IK.I77..$R)"TVTJR"NL<
M?H[9@.40U$U&A)9X_C#+$G>V_%BI8V[9BHE#!-YB[JEU 9@=D-?X[$P; J;M
MZ[3[3:DF/-NNU&'X\3[[<8Y*,->.3WS?LK!66UDONHTT@8KTL=;>165_H@RD
M.ATSUMG^-VN0Z/1&VWFX6-9KV#$NVRC3H#[)F'*1')U"W][7MH MA!K+VBLZ
M^ZI+JOA6U-<U,V-8U5M56,9N97V=980W'HD^OGQ'@=9>:,VW6S0A515%[W5#
M1'/(Q2L.U7P3*,!R$&Q;*0S6Y142ZEZ;"5T2!JRKEDI(C.;M[4AH#3<HHNVI
MFBN?P_$,TTISK)\ R6.(NHP5MBUQ+IY4J";H-E)K)Y1>WBOHG(_&<!P%4215
M[W5?K!R6K%W'-"L:+3O3R3):50>U1U'B.#?65:\A*GC&)Z=-2(LD#%/6Y(P0
MJJBN[O(O5CA=,ZWI-U1NK(R61&;_ ,QQS7:JA+[:*YY1Y_%QSVFAMWL<G"YI
M4[RIR(@,(G>8OJMI%FE]I]J+A=D-KC&78U-.!;54Q&G([O9N"A-2(DV(^Y'D
MQGA<C2HSKC+P&T9@5#I[UZ8](TDSMB.Q7NZWX136-_I=DSS+8M#991B=2U89
M;@=K//E[3Q&/:U9.JXZI5['*R$2UT4UYTBU3AS>5&?:-J#B^1RP=+_U:56UM
MF_8P9H+P)A]IMX%X$*+L_<9->4^.U$83*3:WMG"J*V.(-./F3\ZP?CQ6A!ED
MS52)-PBJ^!%VM!L=><?UFSF$RYXEIQH%+@ZGW4Z:"DVL&;DE-,73[&GF'AW/
MA9V\60V._E:<).16L:M6 THZ=<>MDM,1T3Q^R<GM3+&.CK43)]1<B\6@/9GD
MS++Q"P/8QZZO$E2-&%TGI#_=TLZ==+H92LQU1RB)0Q9)1W9$.AJ@!V?DF66X
M,;G1I,2QV'*LIA"J$D:*?+O+<BZ8Z%Z;P2KL'TIPJ@PC'&'>0I;T&B@,PULK
M)YL 25<6\@#ES7U1"D2WW'"]<2]S//<9E'L'.[S _=GB_LY![NLF@\*/%<SU
MRI'.='Y<HF&1A:KX4#]KB;"S9*$U6Q<F7MZ29)5%5B!:/DB*J;6-+<0)=7;U
M$Z75VM9/CNQ)]=90)#D2= FQ7Q!Z-+B2FB;<;-$(#%45$5.[BNI.G&36^&YY
M@][79+B>4T4HH=M1WE5("5!GPWQWHAM.@G,!(3;@*H&) 1"N/Z7]5E_BO3UU
M'1F(E8=O>S6J'1_529N".W98QDEF^E?AN06#ZHCE+9OMB;S@I!D25-66&9,9
MYJ1'D--OL/L. ZR^RZ".-/,NMJ0.-. 2$)"JHJ+O3NVT+4K4^OS75>$$EF#H
M=I?+KLLU'=LV0<1N)D<6-,&LP&*3P[C?NY$)5%"5EM\Q[-6USR8&GVB6.6<B
M=I]H1BMA)=QBE<+G9CWN669M0Y.>YL,(NR6QE--1XR$ZD&)"!]\'*W2#5P[O
M4[I'O+5"G8XCY3<KT?EV#[(S<ITV<EN;GZ?<A/3L>,VHLEQ2?C''DF\LG$]6
M]'\SI-0-.,YJFKG%LLQZ2LFMM(+AFRXG*X#,J%.A2F7(\N)(;9EPY33C#[;;
MS9@/F?7C]#+JA^)#..\Z2OI-:#?&GBO>=:6/D\4E:3JRZBZI)1,+&64,#5_,
M(H2O%U<>[$9(-(:#SGN0ONE\*]W%^CWK*O[#3^%IN<^#I%K,[66^18S*Q.SL
MK"W9PK-V:2%97=#-QR=.)BLG#'?@.5Y-LOE$\4%R2MF?6_TZ%&2.$E6F=1J:
M18]FX(D(I41W7;99"(2<S*,]J*[T445%W36=,;_/NI+*FFE&)5Z=8;;XUCB3
M-X*+5IF.H\3%6&HG9DJJ_6Q+;<J<O(J[]VK>O>=8+BNFXX_U(9;I?AN(XM,M
M+5*S"Z33727*Z\<@OK0VBR'(RM<VF]O,8AUL=QI&A"*VH$1]YK/Z6GGQK8-M
M^\O\6UO!5.5&+"4C8^#>P3I.,+]958,5_?V147AZFR<?/]C9%1>/J[(J+Z:;
M=4FIU:_'/+=6-<J%J_CM!RO0J#"=,,4CXZT^1>O<\9OL@O9*%O4-[Y(FY4+^
MXM0&,;G,2+I_$=.;;.X#0<A5.13<;:B0F'$3UJG.QBLKY:JFY25]57BN]1];
MNW;O0\'V]DX<-DX?4]#9.'G^SMC5\(<JLSI-2^:;_7),8\<C"7UFU@N[O!]V
MOUMV+)OX+D5)^]OLHW]]%[UQEYL'6G0-MUIP!-MQLQ43;< D43 Q545%145%
MVE9OIW12/]U?7&XL;K3"PB,&==I]DLA7K&_T=LWQ! ANTVYR51]IN\;I%$0-
MY^%-(.\BU6EO5YKE14<%I&:_'+3-9^9XQ7,B"-BS78QG'MDH*]H11-PLQ@1-
MV_P[-UC_ %?6H1FA8$78>D/3[76"I'%!;[2WK])XMJ\1(GKU-XE=7B?,NTJI
MULZI-<-0L?G!V<O$[K4/(F\*D#V2L$KF$UTV#B:FXR2B9>)\QHJ\RKO7O*;0
MK6\[W4KI&N+-&8U:POC^6Z'3[:?VT[),# FG)5SBLE]\WK''%<$%=(I<!6I)
M2&9]5>5I2#KKJM@VU><N#.K)90K&*U,BE)K;2-#LZZ03#PJ;$AEI]DMX. )H
MHIWF"=4>-UJ1\4ZF\4*!E3D6.@QX^K&E\2JI+.1()E$9C%DF$3*=UI"$3DR8
M4YW>9=HH][H3I=:U9U>H&340ZN:LL2&>PL&M1=28\2[LJBT;Y 1+##J7R?0&
MJ(N\:D5WE]TO>:C=..JL<AH,YJE2JR"-':D6^$9?7JLK%LWH4=-I/*N.6H@]
MV:F#<MCM8SJJP^Z)9WT]:UTGDK,<*L%&/814?<Q_,<:EJ;N/9OB,]YIA;/&<
ME@"CT=Q1!YD^TC2&V93#[#?F3;++9NNNF#;338$;CCAD@@VV HI&9DJ(B(BJ
MJKM+ZD==<>6!U-:W4,9B'CMK#[&TT;TLE'&LHF)2F)#(RJ_-<LE,,S;T"5"B
M@S$A*#;K$I7NYGGN,RCV#G=Y@?NSQ?V<@]Y.Z^-%,;=/2S5.U8;U_IZF)S1\
M!U3L7VHL;/G&HX(,3&M3I#H#+<(>5G(N<C<4K-AL.\BUFAG4[K5IQ0PN;Q;$
MZ//;US"&U)352]H]E*G8@9[W"5"*$I(I*J+QV6F#J^M2B$T^RKSVD/3[(M>2
M0XXXXJ7K^D[EX+HDXO(:2$-H40041$4275:F=8.N]S2SP)NPQZISJSPS&K%H
MBYU9L<:P@L<HK!E#1%0'HYB*HFY$W)L1F1&9DI$1*I$1$N\B(EWJI*J[U5>Z
M942RM0] ,MLV).I^B5C9+%@6+@L%$3*L*L'V)H8CF\-D@YGVFECV33(,3 ,0
M8=CZ<:]:7/W4C -4L9A95C#F0T-GC-TE?,5QHFK"FMF&),=Z/)8<;[0.UB21
M%'HKS\9QIYSS+KQ^AEU0_$AG'>=)7TFM!OC3Q7O.JZM>B/,5V;Y;2ZL4<MSM
M5:M(6IN)T65VDN(;QF9LQ<JGV,(O  O1'!!$ 1[_ %D^F;J'\2'3OWNM<<"(
M%;KL2GJHMJZJC5:@XE:&/*A"J"80U%2W^L1>;<N[<O[R_P 6S%B [F[2**&7
M^%*A<K)I]94CDUNV3C]O["ILBHO#U-DX^?[&R*B\?5VU'T<L)2-Q=2L3BY'1
MM.N>M/)<#?DF]#B-*7!^=CEY,?=44WD%>._[E/[A<>><!IIH#<==<,0;;; 5
M(W'#)4$  455551$1-NNO5=N>-A19]J'%M<$=%UIT5T^P1Z;IS@[S:MD0F3^
M#5=1VB@I-\X[T7CO(54>&R</J>AL/#S_ &=DX;9!+Y45RJD4]BTBH/A2UB0W
MB0B(>7EBS'%X<51-R>';32D5N0^EQG^&U78Q$4Y3OE'(JZ)V481!PB?<[;<"
M()*I*G!5X=]F^@FN&,M93I[G=;XG8QD,8UI4SXYC)J,EQRR[-URGR7'[!L),
M*2(ER.@B&+C1&V;T3)X<O.M!LEM9#6EVN%37/!1W##ARGX6,Y@VV)M8IJ%%@
M1U-^"X9,R1 WH;K[0N=GY@S&C,NR)$AUMAAAALW7GWG31MIEEIM"-QUPR01$
M4555=R;8CUG];F''#RF"]79-H3H)D<8>WQN4TK4^GU,U0JW>96<CCN(#U/1O
MBAUS@C)F@DL6F(W>ZTXU35PV&H.D\0->--@%I79;N0:;0K&9>54%L!)UZ=DF
M S+BMC-"J(<N4SO\'>Z&:>6M:%GI_@UM[].JS+[?;0W<"TSEU]J=38LH;9G7
MY?E3]51/<I(0!:<R+ZWOXF.93*]HVLF",VDK1_5Z##27+QN;8MM%,QW):\39
M7(<%O9$5E947G;D1W6Q?C.-FC@O7&C/4+@L_#\JKR<D5-B(NR\4S6B1XFHN4
MX-D78LP\CQV:H^M=;Y76'4)B2VQ);=9#S"MH:"JLKR\N9T6KIZ6G@RK.VMK.
M<^$:%75M=":?F3ITR2X+;3+0&XX9((HJJB;8IU==;F,PI6K$8(5_I#H1;-1Y
M\32V<CA2*_-]164.1!GZAL-HT]6UF\VJ!PNVD(MF#85W=SSW&91[!SN\P/W9
MXO[.0>\R; <ZH*S*L,S.BM,9RG&[J,$RJO:&ZAO0+2KL(SGK78LR&^8$G!=R
M[T5%W+M?:U:(5MWJ'T?W-D4F/:,C*N,HT/=GR!%G&=12!HWG\722^+%7D!*3
M;N\(\Y6Y:M',\QQKJ?ZML7M<8Z8*UV+=X/@5J$BJONH"4TZKL1YYCF9LJ?2<
M":0WYBHT]=@0M0E[ W)3<*KJX42MK*V)&KZZNKXS,.!7P(;(1X<*%#C@W'BQ
M(L=L6VVVQ$  4$41$1/,^O'Z&75#\2&<=YTE?2:T&^-/%>\TFZZ\*JCF>]["
MCZ,:U>*L*;L/$K>[EV>F>6RE#E;;KZO++N?4RG2YG">N( )N "5.^UD^F;J'
M\2'3OWNO%0V/.\YI9F<Z.WS**N2J>DEW,5I"0@1"<D0!%-ZH.]?7<-^W[R_Q
M;2#:#FE5I>/L;DWD0-#RR6T]'<4<B+<GA(4V3CQ\_P##LG'[?V%39%1>'J;)
MQ\_V-M-M7:9'79>"95674F&RXC1VE.+BQ<@INT540 NZ&3)B$N]-POKM099C
MD]FTQ_)Z:LR"CLHQ(;$^HN(3-A73&23>BMR8D@#3ZR_W!K%>U-H-=J/K#$70
M?3!&S,)H7VH=?81<ANH9LKVL61B^ Q+:P8D*G9MSF(X*J$X"+D<$S)&Y^F=S
MR-H**)R8N28F\V1%NWB@1^VW>@JKN^ILG#ZGH;)PX;)PV153TDVU$4^84:Q6
MTD(H[D7GBL^,MIQ14Y5-I-Z>%4^IPVZ9*! [5MW6W3JSF,[D5'JW'LEK\AM&
MUWOQU$'*ZJ=%50N847>*$2(*]]DFF>JF&X[G^ 9A6NU.2XEE57%MZ2W@.J)]
MG*A2P<;[5AX!=9='E>CO@#K1 X DEYJ5^SVRB/:U3Q2K%[IVU+O@AV\ S,W4
MK=-=1[/DK[.(G.C<>%D3T9YEL%)RTD&2"C^!Z[:4Y[I+ES/:D-)GF,VN.R9K
M#1 )3JERPC,QKJL/M!4)40WXS@D) 9(J*O>P!T*T9O5PB4]V<S6+.69>%Z05
M;0O*Q)?7,[*&361/0G41'H5&S:V0(J%XLH\=J+574UZ#U#=2U>4:P@YI>5"1
M\#TVLA:0U333$)CDH5M84@E1N^LE=L%5L'8K5<I.-EWQ 8B8&*B0DB$)"2;B
M$A7>BBJ+N5%VU\T5K:U:W!%RAS/=* !D68:Z8Z@(62XO K^4E1V/BJ3'J,SW
M!S2:MU4%$W)WFJ'5MDM63&1=0F4)A^!29+:]HWI9IE,FP9T^ 9M-FTUDVH;\
M]F0**8.#11C14XIYA,TGZC=-Z?4#%W5>DU$F1VL#)<1MW&D;"_PW)X!Q[G&[
MAKD'F..Z+<@![*0#S!&T5YFW1U9EU*Z5@Z_,C81/DU='KGC5>**[XL] >\EX
MQJ&,5M.5'ZLXEA)-41NK3PK:87J+AV58#F-&]XM=8GFN/6V+9+42.5"\7M**
M]B0+2O>Y51>1UH"W+X.^J;BLTMFZ*:4SC;=?U9UNAV6%T[U>J-.K*Q;%Y,1<
MUS3QF.9>+/0H"UCKH\CDUGB20LMHJH]7^H$H7866N.?UT)RSJW'0)N7'TVQI
M"F5FG5>^#AMDY'<D6SS)DT_.>:5&Q[S//<9E'L'.[S _=GB_LY![V?46\"%:
MU-K"E5MI5V45B=765=.8<BS8$^%*;=C3(4R,Z3;K3@D#@$HDBHJIM>:J="-]
M2:*YO-=D6-GHAE;DT='KJ2?:R'TPFV@Q+*XTXER'55&X),S:;F(&V1K6 55<
MQ?J/T0SO2Z4LMZ%77-S4G*PS(76-_:%BN=U!V&&Y0T(\5*!.D<B+Z[E7AWS>
M,]-^B6;ZDD,UJ#:9)7UA5^!XTZX*.;\JS^W*!A^.;F=YB$N:V\\B*C0.%N%:
M'5WK3M,=Z@-5X!,651I961I3VB.%V(&CC+MNEHS$L-5;6+R"2)-BPJAHS,%A
M2U!J3LS&C,M1X\=IMAAAAL&F6&6@1MIEEIM!!MIL!01$41$1-R>:=>/T,NJ'
MXD,X[SI*^DUH-\:>*]YENFFHV-UF7X'G>/VF+9=C%RPLBLO*"ZB.P;*NEMB0
M.(#\9XD0P('6RW&!"8B29/J?H'C64:V]*4N7*M*VXH8<G(L^TFKC$Y3E-J92
MUL4ISU/4")@UD49HX#C#8E,\3>,6S[ROTZT1TTS753-[,A\6QO!\>LL@L09)
MP&CG30@,/-UE5&)Q%?ER29BQPWDXX HJI?Z8=0T/'*?4+4'7#*-82QC'KUG(
MW<3I[[ =,<-AT&1VL!HJ-W(VI6!R)#PUTF?#!F0T@R"<[0&^\M*6>)E!N*Z;
M5S1;+D,HEA&=B2! U0D$U9>7<NY=R[7F.60*W8X_;VE)/;45!6YM5->@2@42
M]<*B^P2;EXIL2*B*BH2*BIO145$145%X*BIM)B(*I#>)9, _"/BSI+N:5?JL
M&BAQX[D1? J;)QX^?^'9./V_L*FR*B\/4V3CM9].N33^;,-(Q=M,160X*O6^
MF]K.4_%F5(B>?>Q&^EFP:KN$(<R&V";FRW>;RM)<&O!L]&.E8;?3JB=A2.UJ
M\BU-DRF/?5RI@@7LI+4:UK8]'&<13:-JG)]DE"4JK:$V'.$33/(Y,A>84[-D
MKS%8HGN(D4][\H!W#O7UV_=N151.'#9.&R*J>DFR<-M47D; U3 LH;W&F]$1
M^GEL*:?X[:.\PK_A(FV%7*L*_$TQPG4'/)B*WSM CM">"07755%05:M,V8-M
M>"HX JG@\QDX5JYIU@NJ.'33%V7BNH>)T.9X[(>;0A;>>I<C@6-<;S2&O(:M
M\P[^"IM*GUND&5:*V\SM%?L=%M0+N@8YS^Y<BXQE:9KA-=V7\D(U6RVO\H5X
M;/%@?5?K;C;!&*QV\NQ'!,V>:;[5Q2%YZF#  ?-65 4(6VT0A4MRH2"/SW<S
M^ VC^4W8).H&O'4AG -&9A7TT[3O":]\50$;:G;\)R>S< /7*O82HQ$2CQ1!
M5#@6F#=+."Y'DT#D<#+-6CM-7KI9K2BK=G%CZA3K_'Z.P;Y$4#K(,% ).840
ME)59C1F6H\>.TVPPPPV#3+#+0(VTRRTV@@VTV H(B*(B(FY/,<;S_JAT,CZF
MYAB.->T^@O1U U5PB7#QI+2==!4O!IUG.(QK*.Q:6<EYI90/&T3[G(0H9(OS
M1_\ Y]]3ORT[?-'_ /GWU._+3M\T?_Y]]3ORT[8/H]I1C47#M-].,<K<3PS&
M8DJQGM5%%4L"Q#C'8W$RQN+242(IORYDB1+E/$;KSKCIF:^8MXYKYHMIEJ_4
M1P<""QJ#AE%DS]2KJHKCU)86<)^QHI1*G\]#=8=3T"VFS,5Q75O0R5,(WE32
MK5"=+KVI1O=N;K59JK6ZFQ8T=TU45CQT88;:7E9%K<*CS8CU@:L4<7M7%['(
M].,/RF1V*B'9-^,UEUAS?:@2$I'V.XD5$01W*JLG9]:F?RX(J7C$:!HUCM=+
M='D)!1F;(SVT985'%154H[F]$5-R*N](LW4#4'J+U7E,DTLFMGYAB6'XQ+06
M&Q=%8.*83$R9@79/.:<ESO$% -ZJ)&Y!LM"^EW2S$LBK=WB&:6=._G.?PB[1
M'2*'GV?S,HS*'SNBA*C4X!51'AN$43OI,&:PU*AS8[T27&?!'&9$:0V3+[#S
M9(HFT\T:B2+P5%W;?,<Z9?@EQ/\ !^WS'.F7X)<3_!^WS'.F7X)<3_!^T:="
MZ(^FJ+,A2&9<22QI1BC;T>3'<%YA]EP:]"!UET$(53BBIO[^PQG,,=HLKQNV
M96-:X_DM17WM)9QU5%5BPJK2/*@3&55$7E<;(=Z>#:982NG"MTIOIA/%Y;T,
MOKG3!J(KW,I)#PVHDNZ;,B!DA GD0D#E04W!O%9#FG?4QU!8BRX+ZQX^75VG
M>>)&=-IGL$5RJQ[3YQ^.P^CJJ*JAFV0#SH0$XY\]W,_@-H_E-VCN:B=3'4%E
MS+8L+(CXC7:=X&DET&GNW1'+7'M07&([[ZM*@HJF#8F/.I&+C<&SA=.5?JGD
M, V'!OM<;^ZU-"2<=0(%EX?;26M-W>9T>8MU(*$JJB[PW"E=CF+4=/C6/5$=
M(E30X_60J:FK(HD1C&KJNN8C084<2-50&P$455X<>^^8YTR_!+B?X/V^8YTR
M_!+B?X/V^8YTR_!+B?X/V^8YTR_!+B?X/[W)L'S.CK,GP_,\?N<4RO&KN(U8
M4V0XUD5=)J+VCMX$@38FUEM5S'8\ADT4'&G"%45%7;YCG3+\$N)_@_;YCG3+
M\$N)_@_;YCG3+\$N)_@_:CRK&>C'ITHLDQFXK,@QZ\J]+L7AV=->4TUBQJ;6
MNELP!=BSJZ?&;>9<%4(' 0D7>G?6&0:L=+F KEUFZ4F=FN K<:5Y7/GD)!Y2
MN+33BSQCVR3N0MRG9A-0D$4)%Y Y94K']0NJC"7'&G4B0:G4'3JVIHSQF9M.
M.,9+I);W,EIGF0>3R@"D IO+FWDKRWNO75A9-$ HP%3D.D%*XVYS>N-YV9H_
M?B^"CP01!M47CO7P;1K"ST<R_5NPANJ]%D:K:G9=91!<[0S'QF@Q&9AF,6C0
M-GV:-2X,AI11%45-.?8,,T6TNT]TFQ('4D>US3C#L?PNF<E<@ME-D5^/5]?&
ME3G1%.=]P3><7B1*JJO?ZK1@8)JORVSCZ@UKBBHI*',HC5M;OBB\%$,G.>UO
M15WJVJ_61?W_ .+8T:$?'X:D_"-?Y2\J=K&5>'K9 BB?6-!7P)LK;B$! 2@0
MFBB0$*[E T7<J;E3=Q\&R<>/G_AV3C]O["ILBHO#U-L*U>PA_=<XC:M2GJ]Q
MXV8.04KZ+&O,;LU;0R6MO:QUR.XJ"IM*:.M[G0 DP[5G )Z3\8S*I9L8J$H>
M-ULL2*/:T=FVV1BQ;45FR[$E BD(O,ERJ0\I+YK*P[3RZ!CJ7Z@*^ZQ/3 (<
MEORE@6.=@,3+M6I#0EVD8Z&-+2)3$6[M;J0VZ(O,PY8"1F1&9DI$1*I$1$N\
MB(EWJI*J[U5=M2K_ +/F&JT_CTZN;S]8M[D=;-$-R$C?WQ,=5>**OK>"HF_>
MG#854?239.&R<-M3IRJH*Y3P:T513156ZO:JG04Y/7*A>/<4\&[?OX;]NH;7
M6;%54L+/%]*,;FJWRH"549W+LSCBXJ+VJ/E;T1;AW("M<=_,G+_Y2Z5:UP8Y
M$M>_.TVR-X6U-4C34E9'BIF0\66(\IFT B+>*N26QWHJHA+^_P#Q;%Y_0V<O
M:]OP\;%D$^M_3!'Z_@<1/^5_A+LB*OUD^POUMDX\?/\ P[)Q^W]A4V147AZF
MSF":@3I#VA6HMC'2]52<>3 LF<1F'$SF#'07%.O<8 (]LRVB..Q@;?'G.*++
ML*SK)L2QK;&)'GU]A D,S(,^#,9"1$FPI<<W(\J)*CN";;@$0&!(0JJ*B^:9
MEU!:TW(P<=QJ/XI1T49P%R#/,QG-/^U[!\5B$A'+N[V2RJ<W*K,.,#TN03<9
MAYP,[ZBM89XNY%ETL(]+C\-Y]R@P/#:TG6L9P7%V'UWQJ2@AN*G-N1R9+<?E
MOJ<F0\X>VJ><.-*/MDS*IQQ@R\+C.(TYSR-M/#V?;Y<8[_ I J>$> JH^DFR
M<//]C9.&R<-J:@$T25E^;5D8F^?E4JVFA3[:4\@^%Q&K!J&.[P??-^_>B;]#
M\+LX/B.4WV/%J/F;9B(RAR+4%\LD6'.0%4$F45-,AUA[MZ;H2<57>J_^4NH^
MEY TMAD- \YCKSR@(Q<JJ'6KC&9"O&0=@SY:@L@\2$.^.;@JO*2HLN!.CO0Y
ML*1(B3(DELV9$65&<5F1'D,N(+C3S#H*)B2(HDBHNQ>?T-B14WHN]%1? J;D
MX+L[85P;X9$1OQQ3C%5552)L4\,;ZR?S?_)\"(J^DO\ $NR<>/G_ (=DX_;^
MPJ;(J+P]3:HT$U[MWI.CTE[Q7"\TE=K)E:8RI+I&E;9* N2)6"RI#BJBHA.5
M;A*J(L92%B%9UDV)8UMC$CSZ^P@2&9D&?!F,A(B384N.;D>5$E1W!-MP"(#
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M6>F0TD.785&F4:*_!TBI428W(!(LZBERLA;(4!SER'LW$WM(B?B'AG]5Z/\
MT';\0\,_JO1_Z#M^(>&?U7H_]!V_$/#/ZKT?^@[9+F.)T?DK27J=A2M8\-6+
M'%FIK\PDS?%=6<5A]FTQ';>KLL>&V2.T"-18%]$;%5W*B.]/V66WC>IG2980
M<,8;E/N.S;31O(!ESM,;)#?/>X&.N0[''T99%6XD*KA<RHKXIW.G/Z,K/QIZ
M@[:R?3-U#^)#IW[_ /9]?I7?JU[=;ONST-]@]3>\HOI-:7?DGJ9M>_1EU1_*
MS3/O?V?7Z5WZM>W6[[L]#?8/4WS4V=5L*9:RQF)XI4:E8OXM2Y]4-CR]BTEQ
MXK)CW<!A$5 AV;$V(WSD3;8.+SI9WNE[9ZV8&QV\AJ;B$$TS6NB!O,1N, =D
M/6$YX03<A5#]@A[E(FVD5!27$.L-V3#>=8E0U0HEA%>9,@=8DP)R1I#4AHT4
M2;W$0JF[T%V+RC4V4%$_E2X4E@/K*ANMB!(OH*B[EV7TE_RAV_O;%Z2^IL$6
M#%D3)3R\K4:*RY(?=+_!;99$W#7ZR(NS0X_I5E+4=\D4;#((@8I7=DJJA/A,
MR5VJ:DM F]5['M"7=N%"+<BL3=7=1(-'$)1-VAP6*=K9N 2<6G+^X8B5]?(;
M]'DASFU7P%Z*L2\"P&M:R%MM0+,+M%OLM<4Q('2:N;%'7*L) %N<:@C%8-$3
M>"[)PX[)PV3AP]7[6S55CE-8W=B[N48E;$>ENB"D@*ZZC0D+# J2<SAJ( GA
M5$X[,6>IMB->RBMN)C=(^V_-<3<A*W8VR"<6+N).4@CH\I"O!T%V9IL9J(5+
M6L[E&-":0.T/E$%?DO$I/RY)B*<SKI&X>[B2_NSKS_8QJC^0]YMH/_;-I?\
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:^T3^B_T6/_0OZ%_-!_1/^R_^;_Q-W]P__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140180280499560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Cover Page<br></strong></div></th>
<th class="th"><div>May 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Evolent Health, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">389-6000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0454912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">800 N. Glebe Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Arlington<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">22203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EVH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  04,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001628908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>evh-20220504_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="evh-20220504.xsd" xlink:type="simple"/>
    <context id="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2022-05-04</startDate>
            <endDate>2022-05-04</endDate>
        </period>
    </context>
    <dei:DocumentPeriodEndDate
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV80L2ZyYWc6MzE4NDBiNjViOTA4NDIxMWE4ZThlNmRmODkzZDAzZDcvdGFibGU6MzM3ODk2Yzg2ZWViNDUxNGFjZTc4YmIzYmU1MGVkMGUvdGFibGVyYW5nZTozMzc4OTZjODZlZWI0NTE0YWNlNzhiYjNiZTUwZWQwZV8xLTEtMS0xLTM4MDQy_8dddfbb6-c2a3-4eae-9700-d8e860886e50">2022-05-04</dei:DocumentPeriodEndDate>
    <dei:EntityCentralIndexKey
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV80L2ZyYWc6MzE4NDBiNjViOTA4NDIxMWE4ZThlNmRmODkzZDAzZDcvdGFibGU6MzM3ODk2Yzg2ZWViNDUxNGFjZTc4YmIzYmU1MGVkMGUvdGFibGVyYW5nZTozMzc4OTZjODZlZWI0NTE0YWNlNzhiYjNiZTUwZWQwZV8zLTEtMS0xLTM4MDQy_3883474c-9753-452a-842d-fb3b67114f38">0001628908</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV80L2ZyYWc6MzE4NDBiNjViOTA4NDIxMWE4ZThlNmRmODkzZDAzZDcvdGFibGU6MzM3ODk2Yzg2ZWViNDUxNGFjZTc4YmIzYmU1MGVkMGUvdGFibGVyYW5nZTozMzc4OTZjODZlZWI0NTE0YWNlNzhiYjNiZTUwZWQwZV82LTEtMS0xLTM4MDQy_3574a84c-35bf-48ee-b0d3-c1fa8c1b3dd4">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8yNzc3_fff7ea20-5f39-49a6-8674-3a1f0feb165f">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8xNTc_8dddfbb6-c2a3-4eae-9700-d8e860886e50">2022-05-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8yNzcz_f6ab2b54-e163-4fd8-aac7-5507323b7e1c">Evolent Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6NTc4ZTc0MjU4NTI5NDgwMWJkNmY4ZjM1NDUyNzY5ZjEvdGFibGVyYW5nZTo1NzhlNzQyNTg1Mjk0ODAxYmQ2ZjhmMzU0NTI3NjlmMV8wLTAtMS0xLTM4MDQy_687cfdba-5ca4-45b5-b20a-b304caa3b31b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6NTc4ZTc0MjU4NTI5NDgwMWJkNmY4ZjM1NDUyNzY5ZjEvdGFibGVyYW5nZTo1NzhlNzQyNTg1Mjk0ODAxYmQ2ZjhmMzU0NTI3NjlmMV8wLTItMS0xLTM4MDQy_f785d71f-792a-4c72-bbdd-98300eff6bfc">001-37415</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6NTc4ZTc0MjU4NTI5NDgwMWJkNmY4ZjM1NDUyNzY5ZjEvdGFibGVyYW5nZTo1NzhlNzQyNTg1Mjk0ODAxYmQ2ZjhmMzU0NTI3NjlmMV8wLTgtMS0xLTM4MDQy_de0863b2-0aaf-496c-940b-cb9d37673d95">32-0454912</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6NTc4ZTc0MjU4NTI5NDgwMWJkNmY4ZjM1NDUyNzY5ZjEvdGFibGVyYW5nZTo1NzhlNzQyNTg1Mjk0ODAxYmQ2ZjhmMzU0NTI3NjlmMV8zLTAtMS0xLTM4MDQy_9c949cc2-def5-4c0a-a6e2-8883367cc93f">800 N. Glebe Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6NTc4ZTc0MjU4NTI5NDgwMWJkNmY4ZjM1NDUyNzY5ZjEvdGFibGVyYW5nZTo1NzhlNzQyNTg1Mjk0ODAxYmQ2ZjhmMzU0NTI3NjlmMV8zLTItMS0xLTM4MDQy_6407685a-75e8-4ebd-ba5d-c25a631eb89b">Suite 500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6NTc4ZTc0MjU4NTI5NDgwMWJkNmY4ZjM1NDUyNzY5ZjEvdGFibGVyYW5nZTo1NzhlNzQyNTg1Mjk0ODAxYmQ2ZjhmMzU0NTI3NjlmMV8zLTQtMS0xLTM4MDQy_a428ffcd-6949-4623-984b-ab5e93cb780c">Arlington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6NTc4ZTc0MjU4NTI5NDgwMWJkNmY4ZjM1NDUyNzY5ZjEvdGFibGVyYW5nZTo1NzhlNzQyNTg1Mjk0ODAxYmQ2ZjhmMzU0NTI3NjlmMV8zLTYtMS0xLTM4MDQy_64700199-a9cc-4adb-85ca-f3f9dbb13135">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6NTc4ZTc0MjU4NTI5NDgwMWJkNmY4ZjM1NDUyNzY5ZjEvdGFibGVyYW5nZTo1NzhlNzQyNTg1Mjk0ODAxYmQ2ZjhmMzU0NTI3NjlmMV8zLTgtMS0xLTM4MDQy_fc8a21c4-03c2-4f3c-9f91-a2c9edbcf05b">22203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8yNzc0_28908a77-036a-46b7-93c1-97408fc87be1">571</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8yNzc4_b62cf862-90b3-4709-ba94-0a84c11aa75c">389-6000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8yNzc1_80f3b0d9-96cd-4a59-a38d-22b537f25f5e">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8yNzc5_ae30188b-ac32-4976-b960-17216fb34927">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8yNzgw_306bffd5-1cff-4732-b3d0-e4143aede0d8">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8yNzc2_2dbc592c-3514-48c3-b33a-e63815e9cad8">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6YmViMmZlNThiZjYxNGI3NTg4NjVmNDk2YTg5OWRkOTcvdGFibGVyYW5nZTpiZWIyZmU1OGJmNjE0Yjc1ODg2NWY0OTZhODk5ZGQ5N18xLTAtMS0xLTM4MDQy_e5d9b5fa-491d-4d7e-82f0-1926abafe1f0">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6YmViMmZlNThiZjYxNGI3NTg4NjVmNDk2YTg5OWRkOTcvdGFibGVyYW5nZTpiZWIyZmU1OGJmNjE0Yjc1ODg2NWY0OTZhODk5ZGQ5N18xLTEtMS0xLTM4MDQy_77dcdadc-2e6f-4032-b5cc-7667110a6f6e">EVH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGFibGU6YmViMmZlNThiZjYxNGI3NTg4NjVmNDk2YTg5OWRkOTcvdGFibGVyYW5nZTpiZWIyZmU1OGJmNjE0Yjc1ODg2NWY0OTZhODk5ZGQ5N18xLTItMS0xLTM4MDQy_ed6b157a-2b8d-4ecc-85eb-0ebe4f0ff099">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504"
      id="id3VybDovL2RvY3MudjEvZG9jOjg5ZmUyNmRjMWY2YTQwMDc4ZWNhNWQ1ZjAyNGRmYTI5L3NlYzo4OWZlMjZkYzFmNmE0MDA3OGVjYTVkNWYwMjRkZmEyOV8xL2ZyYWc6MzYxNGE2ZTdmMDQyNGViZWI2OWUwOWZmODZmZmMyMDkvdGV4dHJlZ2lvbjozNjE0YTZlN2YwNDI0ZWJlYjY5ZTA5ZmY4NmZmYzIwOV8yNzgx_a9d80e56-094a-49ad-b18e-9819f6994dce">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M/"V6[3S=?[NF%@D76C%IL-4[J(P_P)U[KJ0(A86Y01X@AUHP6<N#JS3R5$M
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MO ^Z>G?PWMU8E16'W:6R<'0NBC%GX FN KQ?*67?;]SYN?S[8_0?4$L#!!0
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " #H@:1499!YDAD!  #/ P  $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ Z(&D5)E<G",0!@
MG"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " #H@:14:3R$R%\$   *$0  &               @($-"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ Z(&D5)^@&_"Q @
MX@P   T              ( !H@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" #H@:14EXJ[',     3 @  "P              @ %^#P  7W)E;',O+G)E
M;'-02P$"% ,4    " #H@:14Y6B*[#D!   R @  #P              @ %G
M$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ Z(&D5"0>FZ*M    ^ $
M !H              ( !S1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ Z(&D5&60>9(9 0  SP,  !,              ( !LA(
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  _!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="evh-20220504.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CoverPageCoverPage</Role>
      <ShortName>Cover Page Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="evh-20220504.htm">evh-20220504.htm</File>
    <File>a1q22exhibit991.htm</File>
    <File>evh-20220504.xsd</File>
    <File>evh-20220504_def.xml</File>
    <File>evh-20220504_lab.xml</File>
    <File>evh-20220504_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "evh-20220504.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "evh-20220504_def.xml"
     ]
    },
    "inline": {
     "local": [
      "evh-20220504.htm"
     ]
    },
    "labelLink": {
     "local": [
      "evh-20220504_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "evh-20220504_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "evh-20220504.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 28,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "evh",
   "nsuri": "http://www.evolenthealth.com/20220504",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220504.htm",
      "contextRef": "i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:Security12bTitle",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page Cover Page",
     "role": "http://www.evolenthealth.com/role/CoverPageCoverPage",
     "shortName": "Cover Page Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220504.htm",
      "contextRef": "i0c20e18e9b144e9e82eeb9068636377d_D20220504-20220504",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:Security12bTitle",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards.",
        "label": "Document [Domain]",
        "terseLabel": "Document [Domain]"
       }
      }
     },
     "localname": "DocumentDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_DocumentInformationDocumentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Document Information, Document [Axis]",
        "terseLabel": "Document Information, Document [Axis]"
       }
      }
     },
     "localname": "DocumentInformationDocumentAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPageCoverPage"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001628908-22-000061-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628908-22-000061-xbrl.zip
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MPSZ&N+E77K=M]C*6N6WU7G9<COV5 0 #I6P#[S8,\JL\GI126A(U[&B"XV*
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MA)W<X_ R\H,(NX@$IZU[#_E,'?=[<O,"OED$81UT?49F=/6 NJK0[C[GX"7
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M,5\:BV[)_(6LN)=\E-Q-%7G P+T\I'K('U+)U:UY&\^[Q-//CB-*Q;I#:=.
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M2"_-/?L-G,P06Y=K2RC\G\!EEP4)'8C*;8EX-F*/+$C9/LFXE3'$3;.^8TI
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M1R-'(^=T800[5G+3B#DR8NQ+[F%=;IUSG]YS)?3?ZIK+&CD:.1HY&CD:.:5
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ML#'$?,,T(3X?\41,Q<!0*#_U8'XTF"R.-J(3V"*8Q]W$P(DPE\8)O@)7<'4
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MR7;!A&/2[PP/:>"I) U$CTPN1N]L/(N>R%76P7P<KI7%T_+9-BB:%E#J89$
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MUB<$O.J%W@3^&28C_Y?_#U!+ P04    " #H@:14O@ZFK@D5  !-EP  $
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MEE[$"@!M%B>#PO\XRL#NVXF'49:,=V(ZZQ/P<#O?<<C8((DO>#_OU!G(M]S
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M]-X^H<(LFX;VCOWO>&$&8^%X3]/0)M^\88/\DG,!G,OM-R&?>)(QRSBA@K"
M<8M+T+T9$&$-0<"0 L9YY_KQ_/]*09+%>>>"K^VR-"L=;VP-<>2<IRSD1D@A
M,-+WD&K W[YY(L"+,PN64P1S;5XX]T![>NZ!KJSLKO#5]*N9:EE?MO$=YX"7
MN8+OM=_<6RYD/]'F3EQ^Q'[\^[DH=\EEV&6IEP2#&0?IGLUY\RF;\X^]GR2_
MY/-IYXY\?V6+=>_S4V0"R\PSJRPGLH^O#B#*'PHF\K^*4@!EVW*YFP'=<7OV
M4X7<=OA7>Y/ID^^LN4]#KI'_:.1_$[[G8>%[4F%W3CW-M3GMCB[R\_]8VD-%
MPCE%$[]TFN)>0_"5%Y#[2SR0L8(;C)><L2QI+Z;IGLS"*W/\],*Y]^(+[LH1
M\(W\).[G#OO.,$DX91</NO$KGHOCEYO%%A3G"_"*]H7!B?[Y\_#@3@):YI7>
M1T5+?MU@\UL[>'RTO^=L-X\/IQ[B?L,^W?1;I_E^S;_#("D<U.5VT#<7;?30
M83A&'AGRS1G!/OG!<3Z,"[X;8 D*XOQI-)=U2>A/ A5")Q45> 1MR(,:HCLR
MS+IQ I.C+[\EOQC7TR[^>_P?\9^GD.G3"U]G+^7M_X^F?YYP,D/<D/[BP1%%
ME9\<'+%6%1R1->U'CT\LL.>,-^^]+TZ\KYTT#OCCVU]KVP?-KV"1.SOE)=SX
MI2S:YWT<X*E&]"O>U[K8BOYS7'V$%<UGI)55\PU1TN)IY8*JDE;07W%$,C $
MT&X9G;(@<EG2>2Z:>@\(Y@FVRZ!XZ?3E-X;_Q9+D5\>Z."CSSCE[,6;W6,02
MD0@SC%(6BITIL/H3EI%D/(_B-YZL?/W^>A7-I:,\TMI]8^YUQ8WI&'YULWZX
M]?]02P,$%     @ Z(&D5)IZK=:$ @  IP@  !    !E=F@M,C R,C U,#0N
M>'-DU55;;YLP%'[/K_!XGH&0  UJ4FFM*DW*+NI:M6^3@0-8!9O9)DG__6P"
M2TC3KIGVL$F1<CCG^\[5/CZ_V%0E6H&0E+.Y-;9="P%+>$I9/K?N;J_QF76Q
M&(W.WV'\\.%FB:YXTE3 %+H40!2D:$U5@>Y3D(\H$[Q"]UP\TA7!>-&2+GG]
M)&A>*.2YGG=H%9'G30((W0S[B1_B*4E33*;$U5)(PB"&@$SC]WD4Q],@G:9G
M>#8V1B\,,$E\'X=D J&?!'[@IZW3C8QD4D!%D"Z,R6@CYU:A5!TYSGJ]MM<3
MFXO<\5QW[#Q\6GYKH5:'+2E['* WL2A[_,0QYIA(Z.&P*@9H6/%2=Z8 4JK"
M3GCEF))=WYU:B"@E:-PHN.:BNH*,-*6:6PW[T9"29A12W?823&,'@#VS(B('
M]9E4(&N2P%LC+T8(F:;0JN9"(7:4WW5E/)O-G(TITT+;)BYY0E1[,E[L2HO'
M1L1C#T_&]D:FEO.FL$-'E$E%6 *GQ-9?N.?]C1QV(SXMAYYW>@ZM,PF)G?.5
MDP(UDQO_F!Y/0+Y,,"+>BL/(A#&N6A]&T^GJFK*,;Q5:9=*/^AIN(.OOSK,+
M<>2@M'\1$8G09_!UL%,+7H-0%.3^96H=% *RN:6O%.Z/[O>2Q+9.I$<\\S^<
M@S$[F@+E<E=(SU5/M>9*/842MJWYA^NN!9Q:MZ9(O0#:,?_OY:>0G5J^IE!&
M_Z!XP[[5=D33N77)]3OXE>3P2["0 =S=?/S-MFV3.$+O@_7A=GDN7/T"Z1_"
MNQ<5HY:)#'5//'<.N0=>&PGI%[9HY<.#T)$[R"O$A)1)4Y[.&[;^**U3]KWN
MUI SW$/;[[U=U2JV2W Q^@E02P,$%     @ Z(&D5#@H<)D;"   'CL  !0
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M8LFN0@\,0PXWG 0AM;%<6!U'CN9/$.P;Z2D&'F ^J;OU"-AIW7:V_$]QOBX
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MFG%0]!Z0G&[2 9*3VF-O4<?0Z_FAM(LYTYR98"D!+3 %"!$QK7LXUGD<AEQ
M>@']2.0>D+J["0?(3.I[#:AW9ET)<]SM*;464WB;:2(\UG5&JISDVG/I'9;U
M-OTPYW/21Z3XP>L>?V%(3C+GT&'-R>U!_D-?UBV$HVG77,#WP;KJX+I[7ZZK
MLZ-I"XO^8F2_V R]O2[:.7CJHD4#9<HI(I1BQ!@!).:YCY'AMA/2<[,70(SH
M);_S LZ+7K,#P;_O,3L;^@>=\GVWCI)_",G\R;M R=2_>_!"S3@A_[G7EE[D
M>7=:!NA.L.F/9=ES19G#RH KI?JSJH%897)B;50Q4&.H32^D_PIV'[WD]7\A
M]\^8\EE27\^>6 4WJ6]O7MT-]W_ZMR3?O/H?4$L#!!0    ( .B!I%27V9EY
M(@P  &1R   4    979H+3(P,C(P-3 T7VQA8BYX;6S575UOVS@6?>^OT&9?
M=H&R)BF2$HMI%]W,S"+83%NT&<Q@BX7!+R7"V%)65IKDWR\EVXEE2[8HV8KF
M(8EB4Y?G'NOP7EZ*\@__>)C/O.\F6\1I\NX,O8%GGDE4JN/D^MW9KU<_@_#L
M'^]?O?KA+P#\_L\OE]Z/J;J;FR3WSC,C<J.]^SB_\7[39O&'%V7IW/LMS?Z(
MOPL WI<GG:>WCUE\?9-[&&*\_6[V%F.?F0!&@"H: "*T!H((:(\"$3!IF"#R
M]?5;*0G31(> H^)-'# @%*4@$+X)J&*445T:G<7)'V^+7U(LC&>=2Q;EO^_.
M;O+\]NUD<G]__^9!9K,W:78]P1#ZDW7KLU7SAYWV]W[9&G'.)^6[3TT7<5U#
M:Q9-?O_E\JNZ,7,!XF21BT05'2SBMXORQ<M4B;SD_" NK[%%\1]8-P/%2P!A
MX*,W#PM]]OZ5YRWIR-*9^6(BK_C[ZY>+QB[YI&@Q2<QU\<E^-EF<ZJ^YR/)+
M(<W,HB^MY8^WYMW9(I[?SLSZM9O,1/5F9UE6L5J@Y 5*Q J4?VWJ;-(#_I'P
MYKM8CP"N=/?CL3#NX_3CT>!>V?'!G![P1C>](2\OJ)\2/=2U^]15;^BG1WRL
MRR+-Q6R R^*YFPW(L^*%2WNTZJ8PM&<P+?M9#=T;4,U#;A)MEJ-EQ;07ZW=G
M]FBJ33S]G)GS=&[CGC)%\+M8+.Y,=E6<F7V*(I--N2\555@ XC,?$*HEX PI
M *D)=!@Q"AF?YD_7]]0DX->O:RAE?^T[.W/P.&]0;F86Z5VFGF/>?%87R&P,
M*Z)>.$G$W"QNQ>H$B[A(#Y9.O+=X@=H ["T1>TO(7HGYA\FSISVIG@U*X&S$
MW*6J@FM6I!1IMDU*JIQ(>9;KPOI3,K(PZLUU^GUBS5AF,/H?*0[!\K!4:JL.
M)CL?_(=L[8'(U(%/8]5BHE+;P6T.*A],D7FZNYJG[M?,DFH+YLQ+,_NFS9EK
M'*M<T3\E>9P_?M#:7CB+SZG-!6?_B6_/4VVF 3620\U P FU.:_A0%!$ !0A
M@\0WVA=1VV&CN9NQ#1A+I-X*ZFMO"=:S:+T";ONQ8@^SAT>)X_!UXO&A*U5.
M0\-A)CH/"GM,#S8<''9O<R!HT=I]"%C/FG],YR).IA(A0R/L@S#2!A 2(,!)
MJ #38<B%EI0HW5;V5=-CD_I3N>#;$M]_VXM[B[/#@N[.Q(E%W)X$)]G6^]M9
MJEOF!I-GO1N;DFQHT5V&3S.V'^W\8JH"K0+$$:!&AX!P90 /J #<YRQB2@:$
M"5<U5GH8K2B7*#T+TRMPNFNS2F1[B7:F9RBEMF6FDV!KO>^MVZK5P>5;ZU2=
MBNL;=DVKSZW%3,PN;*+^\&_S.,5:^S3R0Z""T,[&J;(9M=((2*@1LS$7T<"X
M9=1;/8Q-S*L,<872*V%Z%J=K%KU-9-L$N@<]P^3.[9GID#0W>-\S7]ZV.G"J
MW.#4;I;<U+![9+Y(HC2;ERLC5T+.S#2,.&)A) &Q0=H&9Y^#D$4:Z, 886!$
M5>2[!N?M3L8FZ:<HM '4^U9"[9 _[U#:/DSW(6JH2.W"4:=HW41"[X"]8WCP
MF-WD6EW8;FS;-7+_-#?9=9Q<_RM+[_.;\W1^*Y+'*6-4$Q01$$I"BHI89)-Q
MS %#F@IA\_& 2[?X7=O/V"2_BE5KK-X2K+="ZQK+ZZEM&]%[$S9,7'?EJD-T
MW\M$SQA?;WO@2+_7P=UXO[^Y^T#PU:B[K+#[H&[L)VP^VD]]JB -@L@0@(Q?
MU,0C&_$EM7-R%%*$#4(AHFU'@+H.QB;]-49O#=(K4+:7?"V)A[7>EYH3B]R1
M%2=Q[W.]LZIKC0XFYWTN;>IX;[ON D987L6YS2T)QY(K%(+ ^!$@3)"BC$:!
M0$Q$!I,(<N@JWK7QL0FW!.6ED8?PW^3?O35<=^4^L==>M5TX.;%B7>GH)-EM
MOWO+]<G@X%+==J5.ICMMNB;;%XE*L]LT*_/WK[G(S7EZ9R?OC^5B*<(1EXHB
MX-L. 2'< .%C#(AA1@BJJ83(+>G>V]_8A+Q**"N87WLE:DNSMT+>:6UZ/^]M
M,_*CL3E,9MZ+R YI>BMZ>J;K^_L8.&UOY?!N^M[NM)XWN*S^7,:)05/A0QQ&
MV@>AP@80*A 0T$B@)*18*#^D?NN%[L9>1CJ</-VSL3KP"K#>IZ3K_2T58MN.
M'#WI&F:\<&>J^^TM=4P<Y^Z6BN67N;FESKG&>UMJ&Q]/_'CJ4^1+/Q0 86WG
M H);\2,A .5V$L^$SR1R7(JKZ>5/)?ZK^[2_^'$/\3O1]9+BW\?44<2/3R9^
M_/+BQR[BQ[W%_\5<QXL\$TE>UIY()&1(N0^TAB$@6'' F=( V=<#J:&-^:WO
MA:_K8*22?P;I6,"K);&MQKM3,XR\V[+20=3UKO?4\Y;1@:5<[]*NBAO:N0OX
MMRS.<Y,4M[[?)?%R2^)B&F)##(XX((Q(^TM*$#*J  T$(@1"B6%K!=?V,#8)
MKT!Z593M)5Q/XV$-]R;GQ")VY,5)Q'M][ZSB>JN#R7BO4YLZWM_07<C%?N+9
MYYLT,1_OYM)D4R*U,= 0X(?<3KUM[ 5A)"( )52$!4HI2=IJ>-OXV.1;XO-*
M@-X287OI[A!W6+5]Z#BQ8!V8<!)KD\N==;IC<#")-KFRJ<[&-AV6R-)9K.(\
M3JY_$58+L9A--2:<*V6 X&$ 2*@H$"+"P-CLF"(E$5*X]2+9COFQB?,9H;>&
MZ+!$MLM>BT6R7IR<6*$N=+@MD35ZW7V1;-?D<,MDC>Y4%LJ:6_4L997U\4_9
MYRS]'ENPTRCRM58B "$IJEEA@($(-08HD(@%E,LPZE;*WNIH;/+=+M,\K>:L
M 7>L:&WSZUC4ZL':P'6M]H1U+VPUL'&<VM:V\9<I;S6XV%CA:FKO/BR<%T8S
M(\HE6Q]+HSB$(,(8 A(@!@1F$& B=$!L&$>,M1T&-@V/3?;GY35LP3DN>U?(
M.JSIKA2<6,,MO7<2;)VKG05:,3:8(.M<V!1@[?O=-X-<V5.GRN;*S-CLF#,:
M B*8MD=%\"4:$9]#@DSK&\(W#8]-<$\;&@IP[KL\2JX.ZZTK R?66SOG.VW?
MV/2T]Y:-TMC@VS0V7:C;FE%Y_RA[KR[CQ%SD9KZ8*D0D]&VH"Z3B@$ D[%S5
M$" Q(S[$7$+:NA2\KZ/1RK&ROZB ZY5X^VW$>N:WO63[LC:4A)T)Z[LK:X>-
M8^[,>C;^DKNS=EP\L$-KMWV'M#?];K(/LEAF4ODT,A K90R@HIC^(A^#,) 0
M,(*AE(I@#EM/?RN6QR;\$ISW;0W/0>=5PEKDOEUI.'7RVY8!M_2WSMON^6_%
MVG )<)T3E0RXMD'/4E215G_*KM+[9$H"&$H9,<L')8!P8<,Q%QS0T# 4:DXX
M59VJ4,]]C$V0V_64<FZ69EZ!M6/M:8-0Q[)3-YH&KCBU8JA[L6F7@^/4F3;L
MODR):=>QQNI235-WD6\]<W#S(9=&,$,ILCIGT ?$< -DR"A@5O>4$BQ#W'K6
MV]S-V*2^\S3,HSQ"M-?#0_\DCPT]^?-"3_BDT#$\(]3MZ:#'?"[HS_'LZ98-
M'K%(8@08UQ@0X0<@]*']5W"?*LQ"SEJO"V\;'YO45S&K .A\R\8.<6V#>#<Z
MAHG>;9CH$+-W7>X9K#<,#ARE=UW9#<\U;8Y2$%N_].$A7DRA$50(:  4" +B
M$Q\(H0C@UA*G,$(\Z/-,HLV^QB;;NBK/Z^<O!?E68.Y7&JLPW:DZUI6_%RB0
MM:>N;Y&LCI1CULDJ]E^R5%;GZ(%J6>TI[L/&!VM#%W9^GHGK*19&$8Q# #E2
M@"B)0!A! B"13&@E[&0]:#M(5"R/;4AX N<5Z-IKOTK78:5W)N'$NF[IOY.
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M,C(P-3 T+FAT;5!+ 0(4 Q0    ( .B!I%2:>JW6A (  *<(   0
M      "  69N  !E=F@M,C R,C U,#0N>'-D4$L! A0#%     @ Z(&D5#@H
M<)D;"   'CL  !0              ( !&'$  &5V:"TR,#(R,#4P-%]D968N
M>&UL4$L! A0#%     @ Z(&D5)?9F7DB#   9'(  !0              ( !
M97D  &5V:"TR,#(R,#4P-%]L86(N>&UL4$L! A0#%     @ Z(&D5.9LRG.H
M!P  <CT  !0              ( !N84  &5V:"TR,#(R,#4P-%]P<F4N>&UL
64$L%!@     &  8 @P$  ).-      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
